<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ARIPIPRAZOLE ORAL SOLUTION- aripiprazole solution </strong><br>Silarx Pharmaceuticals, Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Aripiprazole Oral Solution safely and effectively. See full prescribing information for Aripiprazole Oral Solution.<br><br> 
  ARIPIPRAZOLE oral solution
  Initial U.S. Approval: 2002
</div>
<div class="Warning"><div>
<h1 class="Warning"></h1>
<h1 class="Warning">WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span> and SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS</h1>
<p class="Highlighta">See full prescribing information for complete boxed warning. </p>
<p class="Highlighta">• Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Aripiprazole is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. (5.1)  </p>
<p class="Highlighta">• Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Monitor for worsening and emergence of suicidal thoughts and behaviors. (5.2) </p>
</div></div>
<div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"></h1>
<h1 class="Warning">WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span> and SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS</h1>
<p class="Highlighta">See full prescribing information for complete boxed warning. </p>
<p class="Highlighta">• Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Aripiprazole is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. (5.1)  </p>
<p class="Highlighta">• Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Monitor for worsening and emergence of suicidal thoughts and behaviors. (5.2) </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">
                Aripiprazole is an atypical antipsychotic. The oral formulation is indicated for: <br>
                • <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> 14.1) <br>
                • Acute Treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> and Mixed Episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>  (14.2) <br>  (<a href="#section-2">2</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<table border="1"><tbody class="Headless">
<tr class="First">
<td></td>
<td>
<span>Initial</span><span>Dose</span>
</td>
<td>
<span>Recommended</span><span>Dose</span>
</td>
<td>
<span>Maximum</span><span>Dose</span>
</td>
</tr>
<tr>
<td><span><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> – adults (2.1) </span></td>
<td><span>10-15 mg /day </span></td>
<td><span>10-15 mg /day </span></td>
<td><span>30 mg /day </span></td>
</tr>
<tr>
<td><span><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> – adolescents (2.1) </span></td>
<td><span>2 mg /day </span></td>
<td><span>10 mg /day </span></td>
<td><span>30 mg /day </span></td>
</tr>
<tr>
<td><span>Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> – adults: monotherapy (2.2) </span></td>
<td><span>15 mg /day </span></td>
<td><span>15 mg /day </span></td>
<td><span>30 mg /day </span></td>
</tr>
<tr>
<td><span>Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> – adults: adjunct to lithium or valproate (2.2) </span></td>
<td><span>10-15 mg /day </span></td>
<td><span>15 mg /day </span></td>
<td><span>30 mg /day </span></td>
</tr>
<tr class="Last">
<td><span>Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> – pediatric patients: monotherapy or as an adjunct to lithium or valproate (2.2)</span></td>
<td><span>2 mg /day </span></td>
<td><span>10 mg /day </span></td>
<td><span>30 mg /day </span></td>
</tr>
</tbody></table>
<ul>
<li><span>          Oral formulations: Administer once daily without regard to meals (2) </span></li>
<li><span>          Known CYP2D6 poor metabolizers: Half of the usual dose (2.7) </span></li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li><span>    Oral Solution: 1 mg/mL (3) </span></li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Aripiprazole (4)  (<a href="#section-5">5</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li class="CM6"><span class="Italics">Cerebrovascular Adverse Reactions in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>- Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>: Increased incidence of cerebrovascular adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack, including fatalities) (5.2)  </span></li>
<li><span class="Italics"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>:Manage with immediate discontinuation and close monitoring (5.4) </span></li>
<li><span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>:   </span>Discontinue if clinically appropriate (5.5) </span></li>
<li><span><span class="Italics">Metabolic Changes:   </span> Atypical antipsychotic drugs have been associated with metabolic changes that include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>/diabetesmellitus, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (5.6)</span></li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>/DiabetesMellitus:</span><span>Monitor glucose regularly in patients with and at risk for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (5.6) </span>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>:  </span><span> Undesirable alterations in lipid levels have been observed in patients treated with atypical antipsychotics (5.6)</span>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>:  </span><span> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> has been observed with atypical antipsychotic use. Monitor weight (5.6)</span>
</li>
<li><span><span class="Italics"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>:   </span>Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (5.7)</span></li>
<li><span><span class="Italics"> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>:</span> have been reported with antipsychotics including aripiprazole. Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of aripiprazole should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors (5.8)  </span></li>
<li><span><span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>:   </span>Use cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold (5.9)</span></li>
<li><span><span class="Italics">Potential for Cognitive and Motor Impairment:    </span> Use caution when operating machinery (5.10)</span></li>
<li><span><span class="Italics"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>:    </span>The possibility of a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> is inherent in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar disorder. Closely supervise high-risk patients (5.12)</span></li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<span>Commonly observed adverse reactions (incidence ≥5% and at least twice that for placebo) were (6.1): <br>
			  
                  •	Adult patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>: <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> <br>
•	Pediatric patients (13 to 17 years) with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>: <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> <br>
•	Adult patients (monotherapy) with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>: <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, sedation, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span> <br>
•	Adult patients (adjunctive therapy with lithium or valproate) with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>: <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span> <br>
•	Pediatric patients (10 to 17 years) with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivary hypersecretion</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> <br><br></span><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Silarx Pharmaceuticals, Inc at 1-888-974-5279 or FDA at 1-800-FDA-1088 or <span class="Bold"><span class="Italics">www.fda.gov/medwatch.</span></span></span>  (<a href="#section-7">7</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><table width="100%">
<caption><span> Dosage adjustment due to drug interactions (7.1):</span></caption>
<tbody class="Headless">
<tr class="First">
<td> Factors</td>
<td> Dosage Adjustments for Aripiprazole </td>
</tr>
<tr>
<td> Known CYP2D6 Poor Metabolizers </td>
<td> Administer half of usual dose </td>
</tr>
<tr>
<td> Known CYP2D6 Poor Metabolizers and strong CYP3A4 inhibitors
                  </td>
<td> Administer a quarter of usual dose </td>
</tr>
<tr>
<td> Strong CYP2D6 or CYP3A4 inhibitors </td>
<td> Administer half of usual dose </td>
</tr>
<tr>
<td> Strong CYP2D6 and CYP3A4 inhibitors
                  </td>
<td> Administer a quarter of usual dose </td>
</tr>
<tr class="Last">
<td>
                    Strong CYP3A4 inducers
                  </td>
<td> Double usual dose over 1 to 2 weeks </td>
</tr>
</tbody>
</table></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<span>• Pregnancy: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure (8.1)<br>• Nursing Mothers: Discontinue drug or nursing, taking into consideration importance of drug to the mother (8.3)</span><br><br><span class="Bold">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide
                </span><br><br><span class="Bold">Additional pediatric use information is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information. </span>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-2" class="toc"></a></h1>
<h1><a href="#section-2" class="toc">  1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-3" class="toc">  2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-3.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></a></h2>
<h2><a href="#section-3.2" class="toc">2.2 <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span></a></h2>
<h2><a href="#section-3.3" class="toc">2.7 Dosage Adjustments for Cytochrome P450 Considerations</a></h2>
<h2><a href="#section-3.4" class="toc">  2.8 Dosing of Oral Solution
</a></h2>
<h1><a href="#section-4" class="toc">  3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-5" class="toc">  4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-6" class="toc">  5.WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">  5.1 Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>- Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> 
</a></h2>
<h2><a href="#section-6.2" class="toc">  5.2 Cerebrovascular Adverse Events, Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> 
</a></h2>
<h2><a href="#section-6.3" class="toc">  5.3 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults 
</a></h2>
<h2><a href="#section-6.4" class="toc">  5.4 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)
</a></h2>
<h2><a href="#section-6.5" class="toc">  5.5 <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> 
</a></h2>
<h2><a href="#section-6.6" class="toc">5.6 Metabolic Changes </a></h2>
<h2><a href="#section-6.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></a></h2>
<h2><a href="#section-6.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> </a></h2>
<h2><a href="#section-6.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> </a></h2>
<h2><a href="#section-6.10" class="toc">5.10 Potential for Cognitive and Motor Impairment </a></h2>
<h2><a href="#section-6.11" class="toc">5.11 Body Temperature Regulation </a></h2>
<h2><a href="#section-6.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> </a></h2>
<h2><a href="#section-6.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> </a></h2>
<h1><a href="#section-7" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">  6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-7.2" class="toc">  6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-8" class="toc">  7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">  7.1 Drugs Having Clinically Important Interactions with Aripiprazole
</a></h2>
<h2><a href="#section-8.2" class="toc">  7.2 Drugs Having No Clinically Important Interactions with Aripiprazole
</a></h2>
<h1><a href="#section-9" class="toc">  8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-9.1" class="toc">  8.1 Pregnancy
</a></h2>
<h2><a href="#section-9.2" class="toc">  8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-9.3" class="toc">  8.4 Pediatric Use
</a></h2>
<h2><a href="#section-9.4" class="toc">  8.5 Geriatric Use
</a></h2>
<h2><a href="#section-9.5" class="toc">  8.6 CYP2D6 Poor Metabolizers
</a></h2>
<h2><a href="#section-9.6" class="toc">  8.7 Hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-9.7" class="toc">  8.8 Other Specific Populations
</a></h2>
<h1><a href="#section-10" class="toc">  9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</a></h1>
<h2><a href="#section-10.1" class="toc">  9.1 Controlled Substance
</a></h2>
<h2><a href="#section-10.2" class="toc">  9.2 Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>
</a></h2>
<h1><a href="#section-11" class="toc">  10 OVERDOSAGE
</a></h1>
<h2><a href="#section-11.1" class="toc">  10.1 Human Experience
</a></h2>
<h2><a href="#section-11.2" class="toc">  10.2 Management of Overdosage
</a></h2>
<h1><a href="#section-12" class="toc">  11 DESCRIPTION
</a></h1>
<h1><a href="#section-13" class="toc">  12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-13.1" class="toc">  12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-13.2" class="toc">  12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-13.3" class="toc">  12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-14" class="toc">  13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-14.1" class="toc">  13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h2><a href="#section-14.2" class="toc">  13.2 Animal Toxicology and/or Pharmacology
</a></h2>
<h1><a href="#section-15" class="toc">  14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-15.1" class="toc">  14.1 <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>
</a></h2>
<h2><a href="#section-15.2" class="toc">  14.2 Bipolar Disorder
</a></h2>
<h1><a href="#section-16" class="toc">  16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h2><a href="#section-16.1" class="toc">  16.1 How Supplied
</a></h2>
<h2><a href="#section-16.2" class="toc">  16.2 Storage
</a></h2>
<h1><a href="#section-17" class="toc">  17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<h1></h1>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Lfce62390-d52f-4598-890f-345c401c43a6"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"></p>
</div>
<div class="Warning">
<a name="L2c54bfd2-d48a-4bdc-b821-0e2b94f36302"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span> and SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS</p>
<p>Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Aripiprazole is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> [see Warnings and Precautions (5.1)]. </p>
<p>Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.2)]. </p>
<p>In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.2)].</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="L09e680ac-cd8a-49d4-acf5-89b9ba88bd74"></a><a name="section-2"></a><p></p>
<h1>  1 INDICATIONS AND USAGE
</h1>
<p class="First">Aripiprazole Oral Solution are indicated for the treatment of:<br>
                • <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> [see CLINICAL STUDIES (14.1)] <br>
                • Acute Treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> and Mixed Episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> [see CLINICAL STUDIES (14.2)] 
				</p>
<p><span class="Bold">
                Additional pediatric use information is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information. </span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Lce9e1524-3009-4f91-9de1-c81d0024f530"></a><a name="section-3"></a><p></p>
<h1>  2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="L4a4f94f7-9c21-42b7-af22-aac2780ada47"></a><a name="section-3.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></h2>
<p class="First">Adults</p>
<p>The recommended starting and target dose for aripiprazole is 10 mg/day or 15 mg/day administered on a once-a-day schedule without regard to meals. Aripiprazole has been systematically evaluated and shown to be effective in a dose range of 10 mg/day to 30 mg/day, when administered as the tablet formulation; however, doses higher than 10 mg/day or 15 mg/day were not more effective than 10 mg/day or 15 mg/day. Dosage increases should generally not be made before 2 weeks, the time needed to achieve steady-state [see CLINICAL STUDIES (14.1)].<br><br>Maintenance Treatment: Maintenance of efficacy in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was demonstrated in a trial involving patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer. These patients were discontinued from those medications and randomized to either aripiprazole 15 mg/day or placebo, and observed for relapse [see CLINICAL STUDIES (14.1)]. Patients should be periodically reassessed to determine the continued need for maintenance treatment.</p>
<p>Adolescents</p>
<p>DThe recommended target dose of aripiprazole is 10 mg/day. Aripiprazole was studied in adolescent patients 13 to 17 years of age with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> at daily doses of 10 mg and 30 mg. The starting daily dose of the tablet formulation in these patients was 2 mg, which was titrated to 5 mg after 2 days and to the target dose of 10 mg after 2 additional days. Subsequent dose increases should be administered in 5 mg increments. The 30 mg/day dose was not shown to be more efficacious than the 10 mg/day dose. Aripiprazole can be administered without regard to meals [see CLINICAL STUDIES (14.1)].Patients should be periodically reassessed to determine the need for maintenance treatment.</p>
<p>Switching from Other Antipsychotics</p>
<p>There are no systematically collected data to specifically address switching patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> from other antipsychotics to aripiprazole or concerning concomitant administration with other antipsychotics. While immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, more gradual discontinuation may be most appropriate for others. In all cases, the period of overlapping antipsychotic administration should be minimized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lcda30ed6-9e65-4e62-9e88-5e2c3c2b3b4e"></a><a name="section-3.2"></a><p></p>
<h2>2.2 <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span></h2>
<p class="First">Acute Treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> and Mixed Episodes</p>
<p>Adults: The recommended starting dose in adults is 15 mg given once daily as monotherapy and 10 mg to 15 mg given once daily as adjunctive therapy with lithium or valproate. Aripiprazole can be given without regard to meals. The recommended target dose of aripiprazole is 15 mg/day, as monotherapy or as adjunctive therapy with lithium or valproate. The dose may be increased to 30 mg/day based on clinical response. The safety of doses above 30 mg/day has not been evaluated in clinical trials.</p>
<p>Pediatrics: The recommended starting dose in pediatric patients (10 to 17 years) as monotherapy is 2 mg/day, with titration to 5 mg/day after 2 days, and a target dose of 10 mg/day after 2 additional days. Recommended dosing as adjunctive therapy to lithium or valproate is the same. Subsequent dose increases, if needed, should be administered in 5 mg/day increments. Aripiprazole can be given without regard to meals [see CLINICAL STUDIES (14.2)].</p>
<p><span class="Bold">Additional pediatric use information is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L3b1d3dbd-58d4-46e6-8ae8-7599d8c06c58"></a><a name="section-3.3"></a><p></p>
<h2>2.7 Dosage Adjustments for Cytochrome P450 Considerations</h2>
<p class="First">
                 Dosage adjustments are recommended in patients who are known CYP2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers (see Table 1). When the coadministered drug is withdrawn from the combination therapy, aripiprazole dosage should then be adjusted to its original level. When the coadministered CYP3A4 inducer is withdrawn, aripiprazole dosage should be reduced to the original level over 1 to 2 weeks. Patients who may be receiving a combination of strong, moderate, and weak inhibitors of CYP3A4 and CYP2D6 (e.g., a strong CYP3A4 inhibitor and a moderate CYP2D6 inhibitor or a moderate CYP3A4 inhibitor with a moderate CYP2D6 inhibitor), the dosing may be reduced to one-quarter (25%) of the usual dose initially and then adjusted to achieve a favorable clinical response.                   
                 
                </p>
<p><span class="Bold">Table 1: Dose Adjustments for Aripiprazole in Patients who are known CYP2D6 Poor Metabolizers and Patients Taking Concomitant CYP2D6 Inhibitors, 3A4 Inhibitors, and/or CYP3A4 Inducers </span></p>
<table width="100%">
<col width="61%">
<col width="39%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">Factors </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">Dosage Adjustments for Aripiprazole </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Known CYP2D6 Poor Metabolizers </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Administer half of usual dose </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Known CYP2D6 Poor Metabolizers taking concomitant strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Administer a quarter of usual dose </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Strong CYP2D6 (e.g., quinidine, fluoxetine, paroxetine) <span class="Bold">or </span>CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Administer half of usual dose </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Strong CYP2D6 <span class="Bold">and </span>CYP3A4 inhibitors </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Administer a quarter of usual dose </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Strong CYP3A4 inducers (e.g., carbamazepine, rifampin) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Double usual dose over 1 to 2 weeks </p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L5a7d5107-46d9-4314-923e-02f09fc5e488"></a><a name="section-3.4"></a><p></p>
<h2>  2.8 Dosing of Oral Solution
</h2>
<p class="First"><span><span>The oral solution can be substituted for tablets on a mg-per-mg basis up to the 25 mg dose level. Patients receiving 30 mg tablets should receive 25 mg of the solution <span class="Italics">[see CLINICAL PHARMACOLOGY </span><span class="Italics">(12.3)]</span>.</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Lf7c49dae-4754-420f-8ccd-adb324758d37"></a><a name="section-4"></a><p></p>
<h1>  3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Aripiprazole Oral Solution (1 mg/mL) is a clear, colorless to light yellow solution, supplied in child-resistant bottles along with a calibrated oral dosing cup</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="L86923187-dfef-4090-b200-4e36c28c39a5"></a><a name="section-5"></a><p></p>
<h1>  4 CONTRAINDICATIONS
</h1>
<p class="First">
             Aripiprazole is contraindicated in patients with a history of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to aripiprazole. Reactions have ranged from <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>/<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> [see ADVERSE REACTIONS (6.2)].

            </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="L277689ed-261f-4042-88a6-9062da904286"></a><a name="section-6"></a><p></p>
<h1>  5.WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Lb1f19132-11a5-4194-9608-39f0ff861c83"></a><a name="section-6.1"></a><p></p>
<h2>  5.1 Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>- Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> 
</h2>
<p class="First"><span class="Bold"><span><span>Increased Mortality</span></span></span></p>
<p><span></span></p>
<p><span><span><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Aripiprazole is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see </span></span><span class="Bold"><span class="Italics">BOXED WARNING]</span></span><span class="Bold">.</span></span></span></p>
<p><span><span><span class="Bold">Safety Experience in Elderly Patients with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> Associated with Alzheimer’s Disease </span></span></span></p>
<p>
                  
                    In three, 10-week, placebo-controlled studies of aripiprazole in elderly patients with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> associated with Alzheimer’s disease (n=938; mean age: 82.4 years; range: 56- 99 years), the adverse reactions that were reported at an incidence of ≥3% and aripiprazole incidence at least twice that for placebo were <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> [placebo 2%, aripiprazole 5%], <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (including sedation) [placebo 3%, aripiprazole 8%], and <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span> (primarily, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>) [placebo 1%, aripiprazole 5%], excessive <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> [placebo 0%, aripiprazole 4%], and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> [placebo 1%, aripiprazole 4%].
                  
                </p>
<p>The safety and efficacy of aripiprazole in the treatment of patients with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> associated with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> have not been established. If the prescriber elects to treat such patients with aripiprazole, assess for the emergence of difficulty swallowing or excessive <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, which could predispose to <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span> or <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> [see also BOXED WARNING].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Ld3ddd32c-e739-45f3-b65c-9d229f4fce91"></a><a name="section-6.2"></a><p></p>
<h2>  5.2 Cerebrovascular Adverse Events, Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> 
</h2>
<p class="First">
                  In placebo-controlled clinical studies (two flexible dose and one fixed dose study) of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, there was an increased incidence of cerebrovascular adverse events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack), including fatalities, in aripiprazole -treated patients (mean age: 84 years; range: 78-88 years). In the fixed-dose study, there was a statistically significant dose response relationship for cerebrovascular adverse events in patients treated with aripiprazole. Aripiprazole is not approved for the treatment of patients  with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> [see also BOXED WARNING].
                </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a46148f3-9a1b-4bb0-8d99-e26c695cd83e"></a><a name="section-6.3"></a><p></p>
<h2>  5.3 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults 
</h2>
<p class="First">
                  Patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD), both adult and pediatric, may experience worsening of their <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> is a known risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term, placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with MDD and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.
                </p>
<p>
				The pooled analyses of placebo-controlled trials in children and adolescents with MDD, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span> (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in Table 2.
				</p>
<p><span class="Bold"><span>Table 2</span></span></p>
<table border="1"><tbody class="Headless">
<tr class="First">
<td><p class="First"><span><span class="Bold">Age Range</span></span></p></td>
<td><p class="First"><span><span class="Bold">Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated</span></span></p></td>
</tr>
<tr>
<td><p class="First"><span></span></p></td>
<td><p class="First"><span><span class="Bold">Increases Compared to Placebo</span></span></p></td>
</tr>
<tr>
<td><p class="First"><span>&lt; 18</span></p></td>
<td><p class="First"><span>14 additional cases</span></p></td>
</tr>
<tr>
<td><p class="First"><span>18 to 24</span></p></td>
<td><p class="First"><span>5 additional cases</span></p></td>
</tr>
<tr>
<td><p class="First"><span></span></p></td>
<td><p class="First"><span><span class="Bold">Decreases Compared to Placebo</span></span></p></td>
</tr>
<tr>
<td><p class="First"><span>25 to 64</span></p></td>
<td><p class="First"><span>1 fewer case</span></p></td>
</tr>
<tr class="Last">
<td><p class="First"><span>≥ 65</span></p></td>
<td><p class="First"><span>6 fewer cases</span></p></td>
</tr>
</tbody></table>
<p>
				No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in any of the pediatric trials. There were <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.				
				</p>
<p>
				It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that the use of antidepressants can delay the recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.
				</p>
<p><span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</span></p>
<p>
				The following symptoms, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, have been reported in adult and pediatric patients being treated with antidepressants for MDD as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.
				</p>
<p>
				Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s presenting symptoms.
				</p>
<p><span class="Bold">Families and caregivers of patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for aripiprazole should be written for the smallest quantity consistent with good patient management, in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
				
				</span></p>
<p><span class="Bold">Screening Patients for Bipolar Disorder:</span>A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.<br><br>It should be noted that aripiprazole is not approved for use in treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in the pediatric population.
				</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L7085abfa-d957-4856-be83-3679bda92f40"></a><a name="section-6.4"></a><p></p>
<h2>  5.4 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)
</h2>
<p class="First">
                  A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) may occur with administration of antipsychotic drugs, including aripiprazole. Rare cases of NMS occurred during aripiprazole `treatment in the worldwide clinical database. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> (<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>), and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. 
                  
                </p>
<p>
                  The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, and primary central nervous system pathology. 
                </p>
<p>
                 The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. 
                </p>
<p>
                  If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.
                </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L43515702-5477-4cb8-b17e-9f0451bcdb21"></a><a name="section-6.5"></a><p></p>
<h2>  5.5 <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> 
</h2>
<p class="First">
                  A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> is unknown.
                </p>
<p>
                  The risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.
                </p>
<p>
                  There is no known treatment for established cases of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and, thereby, may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.
                </p>
<p>
                  Given these considerations, aripiprazole should be prescribed in a manner that is most likely to minimize the occurrence of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically. 
                </p>
<p>
                  If signs and symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> appear in a patient on aripiprazole, drug discontinuation should be considered. However, some patients may require treatment with aripiprazole despite the presence of the syndrome.
                </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lf12aecf0-1cf2-4727-8b9e-1d6ce81d0321"></a><a name="section-6.6"></a><p></p>
<h2>5.6 Metabolic Changes </h2>
<p class="First">Atypical antipsychotic drugs have been associated with metabolic changes that include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>/<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. While all drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>/<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, in some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients treated with atypical antipsychotics. There have been reports of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> in patients treated with aripiprazole [see ADVERSE REACTIONS (6.1, 6.2)]. </p>
<p>Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and the increasing incidence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions in patients treated with the atypical antipsychotics. Because aripiprazole was not marketed at the time these studies were performed, it is not known if aripiprazole is associated with this increased risk. Precise risk estimates for <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions in patients treated with atypical antipsychotics are not available.</p>
<p>Patients with an established diagnosis of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (e.g., <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.</p>
<p>Adults</p>
<p>In an analysis of 13 placebo-controlled monotherapy trials in adults, primarily with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or bipolar disorder, the mean change in fasting glucose in aripiprazole - treated patients (+4.4 mg/dL; median exposure 25 days; N=1057) was not significantly different than in placebo-treated patients (+2.5 mg/dL; median exposure 22 days; N=799). Table 3 shows the proportion of aripiprazole -treated patients with normal and borderline fasting glucose at baseline (median exposure 25 days) that had treatment- emergent high fasting glucose measurements compared to placebo-treated patients (median exposure 22 days).</p>
<p><span class="Bold">Table 3: Changes in Fasting Glucose From Placebo-Controlled Monotherapy Trials in Adult Patients</span></p>
<table width="100%">
<col width="20%">
<col width="42%">
<col width="17%">
<col width="10%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="5"><p class="First"><span class="Bold">Fasting Glucose</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Category Change (at least once) from Baseline</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Treatment Arm</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">n/N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">
<p class="First">Normal to High</p>
<p>(&lt; 100 mg/dL to ≥ 126 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">31/822</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">22/605</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">
<p class="First">Borderline to High</p>
<p>(≥ 100 mg/dL and &lt; 126 mg/dL to ≥ 126 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">31/176</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17.6</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13/142</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9.2</p></td>
</tr>
</tbody>
</table>
<p>At 24 weeks, the mean change in fasting glucose in aripiprazole -treated patients was not significantly different than in placebo-treated patients [+2.2 mg/dL (n=42) and +9.6 mg/dL (n=28), respectively].</p>
<p>Pediatric Patients and Adolescents </p>
<p>In an analysis of two placebo-controlled trials in adolescents with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (13 to 17 years) and pediatric patients with bipolar disorder (10 to 17 years), the mean change in fasting glucose in aripiprazole -treated patients (+4.8 mg/dL; with a median exposure of 43 days; N=259) was not significantly different than in placebo-treated patients (+1.7 mg/dL; with a median exposure of 42 days; N=123).<br><br>Table 4 shows the proportion of patients with changes in fasting glucose levels from the pooled adolescent <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and pediatric bipolar patients (median exposure of 42-43 days).</p>
<p><span class="Bold">Table 4: Changes in Fasting Glucose From Placebo-Controlled Trials in Pediatric and Adolescent Patients</span></p>
<table width="100%">
<col width="43%">
<col width="27%">
<col width="17%">
<col width="8%">
<col width="6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Category Change (at least once) from Baseline</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Indication</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Treatment Arm</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">n/N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First"><span class="Bold">Fasting Glucose</span><br>Normal to High (&lt; 100 mg/dL to ≥ 126 mg/dL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2"><p class="First">Pooled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and Bipolar Disorder</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2/236</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2/110</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First"><span class="Bold">Fasting Glucose</span><br>Borderline to High (≥ 100 mg/dL and &lt; 126 mg/dL to ≥ 126 mg/dL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2"><p class="First">Pooled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and Bipolar Disorder</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1/22</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.5</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0/12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>At 12 weeks in the pooled adolescent <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and pediatric bipolar disorder trials, the mean change in fasting glucose in aripiprazole -treated patients was not significantly different than in placebo-treated patients [+2.4 mg/dL (n=81) and +0.1 mg/dL (n=15), respectively].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></span></p>
<p>Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics. 
				<br><br>There were no significant differences between aripiprazole - and placebo-treated patients in the proportion with changes from normal to clinically significant levels for fasting/nonfasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, fasting triglycerides, fasting LDLs, and fasting/nonfasting HDLs. Analyses of patients with at least 12 or 24 weeks of exposure were limited by small numbers of patients.
</p>
<p><span class="Bold">Adults</span></p>
<p>Table 5 shows the proportion of adult patients, primarily from pooled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar disorder monotherapy placebo-controlled trials, with changes in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (pooled from 17 trials; median exposure 21 to 25 days), fasting triglycerides (pooled from eight trials; median exposure 42 days), fasting LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (pooled from eight trials; median exposure 39 to 45 days, except for placebo-treated patients with baseline normal fasting LDL measurements, who had median treatment exposure of 24 days) and HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (pooled from nine trials; median exposure 40 to 42 days).</p>
<p><span class="Bold">Table 5: Changes in Blood Lipid Parameters From Placebo-Controlled Monotherapy Trials in Adults</span></p>
<table width="100%">
<col width="56%">
<col width="22%">
<col width="12%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Treatment Arm</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">n/N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2">
<p class="First"><span class="Bold">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span></p>
<p>Normal to High (&lt; 200 mg/dL to ≥ 240 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">34/1357</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">27/973</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2">
<p class="First"><span class="Bold">Fasting Triglycerides</span></p>
<p>Normal to High (&lt; 150 mg/dL to ≥ 200 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40/539</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">30/431</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2">
<p class="First"><span class="Bold">Fasting LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span></p>
<p>Normal to High (&lt; 100 mg/dL to ≥ 160 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2/332</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2/268</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2">
<p class="First"><span class="Bold">HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span></p>
<p>Normal to Low (≥ 40 mg/dL to &lt; 40 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">121/1066</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11.4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">99/794</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12.5</p></td>
</tr>
</tbody>
</table>
<p>In monotherapy trials in adults, the proportion of patients at 12 weeks and 24 weeks with changes from Normal to High in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fasting/nonfasting), fasting triglycerides, and fasting LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> were similar between aripiprazole - and placebo- treated patients: at 12 weeks, Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (fasting/nonfasting), 1/71 (1.4%) vs. 3/74 (4.1%); Fasting Triglycerides, 8/62 (12.9%) vs. 5/37 (13.5%); Fasting LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>, 0/34 (0%) vs. 1/25 (4.0%), respectively; and at 24 weeks, Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (fasting/nonfasting), 1/42 (2.4%) vs. 3/37 (8.1%); Fasting Triglycerides, 5/34 (14.7%) vs. 5/20 (25%); Fasting LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>, 0/22 (0%) vs. 1/18 (5.6%), respectively. </p>
<p><span class="Bold">Pediatric Patients and Adolescents </span></p>
<p>Table 6 shows the proportion of adolescents with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (13 to 17 years) and pediatric patients with bipolar disorder (10 to 17 years) with changes in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (pooled from two placebo-controlled trials; median exposure 42 to 43 days) and fasting triglycerides (pooled from two placebo-controlled trials; median exposure 42 to 44 days).</p>
<p><span class="Bold">Table 6: Changes in Blood Lipid Parameters From Placebo-Controlled Monotherapy Trials in Pediatric and Adolescent Patients in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and Bipolar Disorder</span></p>
<table width="100%">
<col width="46%">
<col width="30%">
<col width="13%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Treatment Arm</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">n/N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2">
<p class="First"><span class="Bold">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span></p>
<p>Normal to High (&lt; 170 mg/dL to ≥ 200 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3/220</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0/116</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2">
<p class="First"><span class="Bold">Fasting Triglycerides</span></p>
<p>Normal to High (&lt; 150 mg/dL to ≥ 200 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7/187</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4/85</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2">
<p class="First"><span class="Bold">HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span></p>
<p>Normal to Low (≥ 40 mg/dL to &lt; 40 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">27/236</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11.4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">22/109</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20.2</p></td>
</tr>
</tbody>
</table>
<p>In monotherapy trials of adolescents with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and pediatric patients with bipolar disorder, the proportion of patients at 12 weeks and 24 weeks with changes from Normal to High in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fasting/nonfasting), fasting triglycerides, and fasting LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> were similar between aripiprazole - and placebo-treated patients: at 12 weeks, Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (fasting/nonfasting), 0/57 (0%) vs. 0/15 (0%); Fasting Triglycerides, 2/72 (2.8%) vs. 1/14 (7.1%), respectively; and at 24 weeks, Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (fasting/nonfasting), 0/36 (0%) vs. 0/12 (0%); Fasting Triglycerides, 1/47 (2.1%) vs. 1/10 (10.0%), respectively. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.</p>
<p>Adults</p>
<p>In an analysis of 13 placebo-controlled monotherapy trials, primarily from pooled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar disorder, with a median exposure of 21 to 25 days, the mean change in body weight in aripiprazole -treated patients was +0.3 kg (N=1673) compared to –0.1 kg (N=1100) in placebo-controlled patients. At 24 weeks, the mean change from baseline in body weight in aripiprazole -treated patients was –1.5 kg (n=73) compared to –0.2 kg (n=46) in placebo-treated patients. <br><br>Table 7 shows the percentage of adult patients with <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> ≥7% of body weight by indication.
				</p>
<p><span class="Bold">Table 7: Percentage of Patients From Placebo-Controlled Trials in Adult Patients with <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> ≥7% of Body Weight</span></p>
<table width="100%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>4 to 6 weeks duration.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>3 weeks duration.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="5"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> ≥ 7% of body weight</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Indication</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Treatment Arm</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Patients <br>n (%)</span></p></td>
</tr>
<tr>
<td align="center"><p class="First"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">852</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">69 (8.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">379</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12 (3.2)</p></td>
</tr>
<tr>
<td align="center"><p class="First">Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">719</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">16 (2.2)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">598</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">16 (2.7)</p></td>
</tr>
</tbody>
</table>
<p class="Bold">Pediatric Patients and Adolescents </p>
<p>In an analysis of two placebo-controlled trials in adolescents with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (13 to 17 years) and pediatric patients with bipolar disorder (10 to 17 years) with median exposure of 42 to 43 days, the mean change in body weight in aripiprazole -treated patients was +1.6 kg (N=381) compared to +0.3 kg (N=187) in placebo-treated patients. At 24 weeks, the mean change from baseline in body weight in aripiprazole -treated patients was +5.8 kg (n=62) compared to +1.4 kg (n=13) in placebo-treated patients.<br><br>Table 8 shows the percentage of pediatric and adolescent patients with <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> ≥7% of body weight by indication.</p>
<p><span class="Bold">Table 8: Percentage of Patients From Placebo-Controlled Monotherapy Trials in Pediatric and Adolescent Patients with <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> ≥7% of Body Weight</span></p>
<table width="100%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>4 to 6 weeks duration.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> ≥ 7% of body weight</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Indication</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Treatment Arm</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Patients <br>n (%)</span></p></td>
</tr>
<tr>
<td align="center"><p class="First">Pooled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Aripiprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">381</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 (5.2)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">187</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (1.6)</p></td>
</tr>
</tbody>
</table>
<p>In an open-label trial that enrolled patients from the two placebo-controlled trials of adolescents with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (13 to 17 years) and pediatric patients with bipolar disorder (10 to 17 years), 73.2% of patients (238/325) completed 26 weeks of therapy with aripiprazole. After 26 weeks, 32.8% of patients gained ≥7% of their body weight, not adjusted for normal growth. To adjust for normal growth, z-scores were derived (measured in standard deviations [SD]), which normalize for the natural growth of pediatric patients and adolescents by comparisons to age- and gender-matched population standards. A z-score change less than 0.5 SD is considered not clinically significant. After 26 weeks, the mean change in z-score was 0.09 SD. <br><br>When treating pediatric patients for any indication, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> should be monitored and assessed against that expected for normal growth.</p>
<p><span class="Bold">Additional pediatric use information is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L3d9bba01-195d-4ae6-8092-d26c4270e667"></a><a name="section-6.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></h2>
<p class="First">Aripiprazole may cause <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, perhaps due to its α1-adrenergic receptor antagonism. The incidence of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>-associated events from short-term, placebo-controlled trials of adult patients on oral aripiprazole (n=2467) included (aripiprazole incidence, placebo incidence) <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (1%, 0.3%), postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.5%, 0.3%), and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (0.5%, 0.4%); of pediatric patients 6 to 18 years of age (n=732) on oral aripiprazole included <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (0.5%, 0%), postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.4%, 0 %), and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (0.2%, 0%) [see ADVERSE REACTIONS (6.1)]. </p>
<p>The incidence of a significant orthostatic change in blood pressure (defined as a decrease in systolic blood pressure ≥20 mmHg accompanied by an increase in heart rate ≥25 bpm when comparing standing to supine values) for aripiprazole was not meaningfully different from placebo (aripiprazole incidence, placebo incidence): in adult oral aripiprazole -treated patients (4%, 2%), in pediatric oral aripiprazole -treated patients aged 6 to 18 years (0.4%, 1%). </p>
<p>Aripiprazole should be used with caution in patients with known cardiovascular disease (history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, and treatment with antihypertensive medications) [see DRUG INTERACTIONS (7.1)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L262c1d06-0233-44c9-a54d-6d32d86301d1"></a><a name="section-6.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> </h2>
<p class="First">In clinical trials and/or postmarketing experience, events of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> have been reported temporally related to antipsychotic agents, including aripiprazole. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> has also been reported. </p>
<p>Possible risk factors for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> include pre-existing low white blood cell count (WBC)/absolute neutrophil count (ANC) and history of drug-induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. In patients with a history of a clinically significant low WBC/ANC or drug-induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, perform a complete blood count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of aripiprazole at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p>
<p>Monitor patients with clinically significant <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms or signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treat promptly if such symptoms or signs occur. Discontinue aripiprazole in patients with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count less than 1000/mm3) and follow their WBC counts until recovery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L56860706-c6b8-42f7-a3b8-1f9b774540e4"></a><a name="section-6.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> </h2>
<p class="First">In short-term, placebo-controlled trials, patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> excluded <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> occurred in 0.1% (3/2467) of undiagnosed adult patients treated with oral aripiprazole, in 0.1% (1/732) of pediatric patients (6 to 18 years).</p>
<p>As with other antipsychotic drugs, aripiprazole should be used cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. Conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold may be more prevalent in a population of 65 years or older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L3d8eed29-e9ed-4e0c-b19b-2cd4ad821e6b"></a><a name="section-6.10"></a><p></p>
<h2>5.10 Potential for Cognitive and Motor Impairment </h2>
<p class="First">Aripiprazole, like other antipsychotics, may have the potential to impair judgment, thinking, or motor skills. For example, in short-term, placebo-controlled trials, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (including sedation) was reported as follows (aripiprazole incidence, placebo incidence): in adult patients (n=2467) treated with oral aripiprazole (11%, 6%), in pediatric patients ages 6 to 17 (n=611) (24%, 6%). <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> (including sedation) led to discontinuation in 0.3% (8/2467) of adult patients and 3% (20/732) of pediatric patients (6 to 18 years) on oral aripiprazole in short- term, placebo-controlled trials.<br><br>Despite the relatively modest increased incidence of these events compared to placebo, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with aripiprazole does not affect them adversely. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lb128084e-277e-4d7f-90b0-21c9aee72518"></a><a name="section-6.11"></a><p></p>
<h2>5.11 Body Temperature Regulation </h2>
<p class="First">Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing aripiprazole for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, (e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>) [see ADVERSE REACTIONS (6.2)]. 
              </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L38106937-8af8-4425-9fad-23222282160a"></a><a name="section-6.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> </h2>
<p class="First">The possibility of a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> is inherent in <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> illnesses, bipolar disorder, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for aripiprazole should be written for the smallest quantity consistent with good patient management in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> [see ADVERSE REACTIONS (6.1, 6.2)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L3c863a3f-c8fe-42c3-92e7-aa94e4e977b5"></a><a name="section-6.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> </h2>
<p class="First">Esophageal dysmotility and <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> have been associated with antipsychotic drug use, including aripiprazole. <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonia</span> is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer’s <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Aripiprazole and other antipsychotic drugs should be used cautiously in patients at risk for <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span> [see WARNINGS AND PRECAUTIONS (5.1) and ADVERSE REACTIONS (6.2)].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Laab2487f-03f8-4cf3-9cd6-474d7940623e"></a><a name="section-7"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The following are discussed in more detail in other sections of the labeling:<br>•	Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> [see BOXED WARNING and WARNINGS AND PRECAUTIONS (5.1)] <br>•	Cerebrovascular Adverse Events, Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> [see WARNINGS AND PRECAUTIONS (5.2)]
			<br>• Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults [see BOXED WARNING and WARNINGS AND PRECAUTIONS (5.3)] 		
			
			<br>•	<span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) [see WARNINGS AND PRECAUTIONS (5.4)]<br>•	<span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> [see WARNINGS AND PRECAUTIONS (5.5)] <br>•	Metabolic Changes [see WARNINGS AND PRECAUTIONS (5.6)] <br>•	<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> [see WARNINGS AND PRECAUTIONS (5.7)] <br>•	<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> [see WARNINGS AND PRECAUTIONS (5.8)] <br>•	<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> [see WARNINGS AND PRECAUTIONS (5.9)] <br>•	Potential for Cognitive and Motor Impairment [see WARNINGS AND PRECAUTIONS (5.10)] <br>•	Body Temperature Regulation [see WARNINGS AND PRECAUTIONS (5.11)] <br>•	<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> [see WARNINGS AND PRECAUTIONS (5.12)]<br>•	<span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> [see WARNINGS AND PRECAUTIONS (5.13)]		
			
			</p>
<p>The most common adverse reactions in adult patients in clinical trials (≥10%) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>.</p>
<p>The most common adverse reactions in the pediatric clinical trials (≥10%) were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>.</p>
<p>Aripiprazole has been evaluated for safety in 13,543 adult patients who participated in multiple-dose, clinical trials in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, bipolar disorder, another indication, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> of the Alzheimer’s type, Parkinson’s disease, and <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>, and who had approximately 7619 patient-years of exposure to oral aripiprazole and 749 patients with exposure to aripiprazole injection. A total of 3390 patients were treated with oral aripiprazole for at least 180 days and 1933 patients treated with oral aripiprazole had at least 1 year of exposure.</p>
<p>Aripiprazole has been evaluated for safety in 1,686 patients (6 to 18 years) who participated in multiple-dose, clinical trials in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, or other indications and who had approximately 1,342 patient-years of exposure to oral aripiprazole. A total of 959 pediatric patients were treated with oral aripiprazole for at least 180 days and 556 pediatric patients treated with oral aripiprazole had at least 1 year of exposure.</p>
<p>The conditions and duration of treatment with aripiprazole included (in overlapping categories) double-blind, comparative and noncomparative open-label studies, inpatient and outpatient studies, fixed- and flexible-dose studies, and short- and longer-term exposure.</p>
<p><span class="Bold">Additional pediatric use information is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="L113e9cd0-e4dc-4cc7-a11f-c4081d8b53c8"></a><a name="section-7.1"></a><p></p>
<h2>  6.1 Clinical Trials Experience
</h2>
<p class="First"><span class="Bold">Adult Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<p>The following findings are based on a pool of five placebo-controlled trials (four 4-week and one 6-week) in which oral aripiprazole was administered in doses ranging from 2 mg/day to 30 mg/day.</p>
<p><span class="Italic">Commonly Observed Adverse Reactions</span></p>
<p>The only commonly observed adverse reaction associated with the use of aripiprazole in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (incidence of 5% or greater and aripiprazole incidence at least twice that for placebo) was <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (aripiprazole 8%; placebo 4%).</p>
<p><span class="Bold">Adult Patients with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span><br>Monotherapy</span></p>
<p>The following findings are based on a pool of 3-week, placebo-controlled, bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials in which oral aripiprazole was administered at doses of 15 mg/day or 30 mg/day.</p>
<p><span class="Italic">Commonly Observed Adverse Reactions</span></p>
<p>Commonly observed adverse reactions associated with the use of aripiprazole in patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (incidence of 5% or greater and aripiprazole incidence at least twice that for placebo) are shown in Table 9.</p>
<p><span class="Bold">Table 9: Commonly Observed Adverse Reactions in Short-Term, Placebo-Controlled Trials of Adult Patients with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Treated with Oral Aripiprazole Monotherapy</span></p>
<table width="100%">
<col width="36%">
<col width="36%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Percentage of Patients Reporting Reaction</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Aripiprazole</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Preferred Term</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">(n = 917)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">(n = 753)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Sedation </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Disorder</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Less Common Adverse Reactions in Adults</span></p>
<p>Table 10 enumerates the pooled incidence, rounded to the nearest percent, of adverse reactions that occurred during acute therapy (up to 6 weeks in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and up to 3 weeks in bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>), including only those reactions that occurred in 2% or more of patients treated with aripiprazole (doses ≥2 mg/day) and for which the incidence in patients treated with aripiprazole was greater than the incidence in patients treated with placebo in the combined dataset.</p>
<p><span class="Bold">Table 10: Adverse Reactions in Short-Term, Placebo-Controlled Trials in Adult Patients Treated with Oral Aripiprazole</span></p>
<table width="100%">
<col width="28%">
<col width="25%">
<col width="20%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Adverse reactions reported by at least 2% of patients treated with oral aripiprazole, except adverse reactions which had an incidence equal to or less than placebo.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Percentage of Patients Reporting Reaction</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">System Organ Class </span></p></td>
<td align="center"><p class="First"><span class="Bold">Aripiprazole</span></p></td>
<td align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule"><p class="First"><span class="Bold">    Preferred Term </span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(n = 1843)</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(n = 1166)</span></p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></p></td></tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span> </p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span></p></td></tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td align="center"><p class="First">15</p></td>
<td align="center"><p class="First">11</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </p></td>
<td align="center"><p class="First">11</p></td>
<td align="center"><p class="First">7</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td align="center"><p class="First">11</p></td>
<td align="center"><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </p></td>
<td align="center"><p class="First">9</p></td>
<td align="center"><p class="First">7</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span> </p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">Toothache</span> </p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal Discomfort</span> </p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">Stomach Discomfort</span> </p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p></td></tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p></td>
<td></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">Musculoskeletal Stiffness</span> </p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in Extremity</span> </p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> </p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle Spasms</span> </p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span></p></td></tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td align="center"><p class="First">27</p></td>
<td align="center"><p class="First">23</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </p></td>
<td align="center"><p class="First">10</p></td>
<td align="center"><p class="First">7</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> </p></td>
<td align="center"><p class="First">10</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First">    Sedation </p></td>
<td align="center"><p class="First">7</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Disorder</span> </p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold">Psychiatric Disorders </span></p></td></tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> </p></td>
<td align="center"><p class="First">19</p></td>
<td align="center"><p class="First">17</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td align="center"><p class="First">18</p></td>
<td align="center"><p class="First">13</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> </p></td>
<td align="center"><p class="First">17</p></td>
<td align="center"><p class="First">13</p></td>
</tr>
<tr>
<td><p class="First">    <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span> </p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></p></td>
<td></td>
</tr>
<tr>
<td><p class="First">    Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> </p></td>
<td class="Botrule" align="center"><p class="First">3</p></td>
<td class="Botrule" align="center"><p class="First">2</p></td>
</tr>
</tbody>
</table>
<p>An examination of population subgroups did not reveal any clear evidence of differential adverse reaction incidence on the basis of age, gender, or race.</p>
<p><span class="Bold">Adult Patients with Adjunctive Therapy with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></p>
<p>The following findings are based on a placebo-controlled trial of adult patients with bipolar disorder in which aripiprazole was administered at doses of 15 mg/day or 30 mg/day as adjunctive therapy with lithium or valproate.</p>
<p><span class="Italic">Adverse Reactions Associated with Discontinuation of Treatment</span></p>
<p>In a study of patients who were already tolerating either lithium or valproate as monotherapy, discontinuation rates due to adverse reactions were 12% for patients treated with adjunctive aripiprazole compared to 6% for patients treated with adjunctive placebo. The most common adverse drug reactions associated with discontinuation in the adjunctive aripiprazole-treated compared to placebo-treated patients were <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (5% and 1%, respectively) and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (2% and 1%, respectively).</p>
<p><span class="Italic">Commonly Observed Adverse Reactions</span></p>
<p>The commonly observed adverse reactions associated with adjunctive aripiprazole and lithium or valproate in patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (incidence of 5% or greater and incidence at least twice that for adjunctive placebo) were: <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>.</p>
<p><span class="Bold">Less Common Adverse Reactions in Adult Patients with Adjunctive Therapy in Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></p>
<p>Table 11 enumerates the incidence, rounded to the nearest percent, of adverse reactions that occurred during acute treatment (up to 6 weeks), including only those reactions that occurred in 2% or more of patients treated with adjunctive aripiprazole (doses of 15 mg/day or 30 mg/day) and lithium or valproate and for which the incidence in patients treated with this combination was greater than the incidence in patients treated with placebo plus lithium or valproate.</p>
<p><span class="Bold">Table 11: Adverse Reactions in a Short-Term, Placebo-Controlled Trial of Adjunctive Therapy in Patients with Bipolar Disorder</span></p>
<table width="100%">
<col width="26%">
<col width="31%">
<col width="35%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Adverse reactions reported by at least 2% of patients treated with oral aripiprazole, except adverse reactions which had an incidence equal to or less than placebo.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Lithium or Valproate</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" rowspan="2"><p class="First"><span class="Bold">System Organ Class<br>Preferred Term </span></p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Percentage of Patients Reporting Reaction</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></p></td>
</tr>
<tr>
<td align="center"><p class="First"><span class="Bold">Aripiprazole + Li or Val</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a></p></td>
<td align="center"><p class="First"><span class="Bold">Placebo + Li or Val</span><a href="#footnote-6" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule"><p class="First"><span class="Bold"></span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(n = 253)</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(n = 130)</span></p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td align="center"><p class="First">8</p></td>
<td align="center"><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary Hypersecretion</span> </p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span> </p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span> </span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span> </p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold">Investigations</span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increased</span> </p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> </p></td>
<td align="center"><p class="First">19</p></td>
<td align="center"><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </p></td>
<td align="center"><p class="First">9</p></td>
<td align="center"><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Disorder</span> </p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  Sedation </p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold">Psychiatric Disorders</span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td align="center"><p class="First">8</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> </p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span> </p></td>
<td class="Botrule" align="center"><p class="First">2</p></td>
<td class="Botrule" align="center"><p class="First">1</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Pediatric Patients (13 to 17 years) with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<p>The following findings are based on one 6-week, placebo-controlled trial in which oral aripiprazole was administered in doses ranging from 2 mg/day to 30 mg/day.</p>
<p><span class="Italic">Adverse Reactions Associated with Discontinuation of Treatment</span></p>
<p>The incidence of discontinuation due to adverse reactions between aripiprazole-treated and placebo-treated pediatric patients (13 to 17 years) was 5% and 2%, respectively.</p>
<p><span class="Italic">Commonly Observed Adverse Reactions</span></p>
<p>Commonly observed adverse reactions associated with the use of aripiprazole in adolescent patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (incidence of 5% or greater and aripiprazole incidence at least twice that for placebo) were <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.</p>
<p><span class="Bold">Pediatric Patients (10 to 17 years) with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></p>
<p>The following findings are based on one 4-week, placebo-controlled trial in which oral aripiprazole was administered in doses of 10 mg/day or 30 mg/day.</p>
<p><span class="Italic">Adverse Reactions Associated with Discontinuation of Treatment</span></p>
<p>The incidence of discontinuation due to adverse reactions between aripiprazole-treated and placebo-treated pediatric patients (10 to 17 years) was 7% and 2%, respectively.</p>
<p><span class="Italic">Commonly Observed Adverse Reactions</span></p>
<p>Commonly observed adverse reactions associated with the use of aripiprazole in pediatric patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (incidence of 5% or greater and aripiprazole incidence at least twice that for placebo) are shown in Table 12</p>
<p><span class="Bold">Table 12: Commonly Observed Adverse Reactions in Short-Term, Placebo-Controlled Trials of Pediatric Patients (10 to 17 years) with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Treated with Oral Aripiprazole</span></p>
<table width="100%">
<col width="25%">
<col width="26%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" colspan="2"><p class="First"><span class="Bold">Percentage of Patients Reporting Reaction</span></p></td>
</tr>
<tr>
<td></td>
<td align="center"><p class="First"><span class="Bold">Aripiprazole</span></p></td>
<td align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Preferred Term</span></p></td>
<td align="center"><p class="First"><span class="Bold">(n = 197)</span></p></td>
<td align="center"><p class="First"><span class="Bold">(n = 97)</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td align="center"><p class="First">23</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Disorder</span></p></td>
<td align="center"><p class="First">20</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td align="center"><p class="First">11</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center"><p class="First">11</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></p></td>
<td align="center"><p class="First">10</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></p></td>
<td align="center"><p class="First">8</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary Hypersecretion</span></p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule" align="center"><p class="First">5</p></td>
<td class="Botrule" align="center"><p class="First">1</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Less Common Adverse Reactions in Pediatric Patients (6 to 18 years) with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>, Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> or Other Indications</span><br>Table 13 enumerates the pooled incidence, rounded to the nearest percent, of adverse reactions that occurred during acute therapy (up to 6 weeks in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, up to 4 weeks in bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, up to 8 weeks in one indication, and up to 10 weeks in another indication), including only those reactions that occurred in 2% or more of pediatric patients treated with aripiprazole (doses ≥ 2 mg/day) and for which the incidence in patients treated with aripiprazole was greater than the incidence in patients treated with placebo.</p>
<p><span><span class="Bold"><span>Table 13: </span></span><span class="Bold">Adverse Reactions in Short-Term, Placebo-Controlled Trials of Pediatric Patients (6 to 18 years) Treated with Oral Aripiprazole</span><span class="Bold"></span></span></p>
<table width="100%">
<col width="27%">
<col width="26%">
<col width="19%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Adverse reactions reported by at least 2% of pediatric patients treated with oral aripiprazole, except adverse reactions which had an incidence equal to or less than placebo.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Percentage of Patients Reporting Reaction</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">System Organ Class</span></p></td>
<td align="center"><p class="First"><span class="Bold">Aripiprazole</span></p></td>
<td align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule"><p class="First"><span class="Bold">    Preferred Term</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(n = 732)</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(n = 370)</span></p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span> </p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal Discomfort</span></p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td align="center"><p class="First">8</p></td>
<td align="center"><p class="First">7</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center"><p class="First">8</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary Hypersecretion</span> </p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal Pain Upper</span> </p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>  </p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </p></td>
<td align="center"><p class="First">10</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> </p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span> </p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span> </span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span> </p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Investigations</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increased</span> </p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold">Metabolism and Nutrition Disorders </span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased Appetite</span> </p></td>
<td align="center"><p class="First">7</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased Appetite</span> </p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">Musculoskeletal Stiffness</span> </p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">Muscle Rigidity</span> </p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </p></td>
<td align="center"><p class="First">16</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td align="center"><p class="First">12</p></td>
<td align="center"><p class="First">10</p></td>
</tr>
<tr>
<td><p class="First">  Sedation </p></td>
<td align="center"><p class="First">9</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </p></td>
<td align="center"><p class="First">9</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Disorder</span> </p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">Drooling</span> </p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span> </p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span> </p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></p></td></tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span> </p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr><td colspan="3"><p class="First"><span class="Bold">Skin and Subcutaneous Tissue Disorders </span></p></td></tr>
<tr class="Last">
<td class="Botrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </p></td>
<td class="Botrule" align="center"><p class="First">2</p></td>
<td class="Botrule" align="center"><p class="First">1</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Dose-Related Adverse Reactions<br><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<p>Dose response relationships for the incidence of treatment-emergent adverse events were evaluated from four trials in adult patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> comparing various fixed doses (2, 5, 10, 15, 20, and 30 mg/day) of oral aripiprazole to placebo. This analysis, stratified by study, indicated that the only adverse reaction to have a possible dose response relationship, and then most prominent only with 30 mg, was <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> [including sedation]; (incidences were placebo, 7.1%; 10 mg, 8.5%; 15 mg, 8.7%; 20 mg, 7.5%; 30 mg, 12.6%).</p>
<p>In the study of pediatric patients (13 to 17 years of age) with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, three common adverse reactions appeared to have a possible dose response relationship: <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span> (incidences were placebo, 5.0%; 10 mg, 13.0%; 30 mg, 21.6%); <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (incidences were placebo, 6.0%; 10 mg, 11.0%; 30 mg, 21.6%); and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (incidences were placebo, 2.0%; 10 mg, 2.0%; 30 mg, 11.8%).</p>
<p>Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></p>
<p>In the study of pediatric patients (10 to 17 years of age) with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, four common adverse reactions had a possible dose response relationship at 4 weeks; <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span> (incidences were placebo, 3.1%; 10 mg, 12.2%; 30 mg, 27.3%); <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (incidences were placebo, 3.1%; 10 mg, 19.4%; 30 mg, 26.3%); <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (incidences were placebo, 2.1%; 10 mg, 8.2%; 30 mg, 11.1%); and <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivary hypersecretion</span> (incidences were placebo, 0%; 10 mg, 3.1%; 30 mg, 8.1%).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span><br><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<p>In short-term, placebo-controlled trials in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in adults, the incidence of reported EPS-related events, excluding events related to <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, for aripiprazole-treated patients was 13% vs. 12% for placebo; and the incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>-related events for aripiprazole-treated patients was 8% vs. 4% for placebo. In the short-term, placebo-controlled trial of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in pediatric patients (13 to 17 years), the incidence of reported EPS-related events, excluding events related to <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, for aripiprazole-treated patients was 25% vs. 7% for placebo; and the incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>-related events for aripiprazole-treated patients was 9% vs. 6% for placebo.</p>
<p>Objectively collected data from those trials was collected on the Simpson Angus Rating Scale (for EPS), the Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale (for <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>), and the Assessments of Involuntary Movement Scales (for <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span>). In the adult <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, the objectively collected data did not show a difference between aripiprazole and placebo, with the exception of the Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale (aripiprazole, 0.08; placebo, −0.05). In the pediatric (13 to 17 years) <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trial, the objectively collected data did not show a difference between aripiprazole and placebo, with the exception of the Simpson Angus Rating Scale (aripiprazole, 0.24; placebo, −0.29).</p>
<p>Similarly, in a long-term (26-week), placebo-controlled trial of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in adults, objectively collected data on the Simpson Angus Rating Scale (for EPS), the Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale (for <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>), and the Assessments of Involuntary Movement Scales (for <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span>) did not show a difference between aripiprazole and placebo.</p>
<p>Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></p>
<p>In the short-term, placebo-controlled trials in bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> in adults, the incidence of reported EPS-related events, excluding events related to <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, for monotherapy aripiprazole-treated patients was 16% vs. 8% for placebo and the incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>-related events for monotherapy aripiprazole-treated patients was 13% vs. 4% for placebo. In the 6-week, placebo-controlled trial in bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> for adjunctive therapy with lithium or valproate, the incidence of reported EPS-related events, excluding events related to <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> for adjunctive aripiprazole-treated patients was 15% vs. 8% for adjunctive placebo and the incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>-related events for adjunctive aripiprazole-treated patients was 19% vs. 5% for adjunctive placebo. In the short-term, placebo-controlled trial in bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> in pediatric (10 to 17 years) patients, the incidence of reported EPS-related events, excluding events related to <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, for aripiprazole-treated patients was 26% vs. 5% for placebo and the incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>-related events for aripiprazole-treated patients was 10% vs. 2% for placebo.</p>
<p>In the adult bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials with monotherapy aripiprazole, the Simpson Angus Rating Scale and the Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale showed a significant difference between aripiprazole and placebo (aripiprazole, 0.50; placebo, −0.01 and aripiprazole, 0.21; placebo, −0.05). Changes in the Assessments of Involuntary Movement Scales were similar for the aripiprazole and placebo groups. In the bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials with aripiprazole as adjunctive therapy with either lithium or valproate, the Simpson Angus Rating Scale and the Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale showed a significant difference between adjunctive aripiprazole and adjunctive placebo (aripiprazole, 0.73; placebo, 0.07 and aripiprazole, 0.30; placebo, 0.11). Changes in the Assessments of Involuntary Movement Scales were similar for adjunctive aripiprazole and adjunctive placebo. In the pediatric (10 to 17 years), short-term, bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trial, the Simpson Angus Rating Scale showed a significant difference between aripiprazole and placebo (aripiprazole, 0.90; placebo, −0.05). Changes in the Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale and the Assessments of Involuntary Movement Scales were similar for the aripiprazole and placebo groups.</p>
<p><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span></p>
<p>Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> is observed in males and younger age groups.</p>
<p>Additional Findings Observed in Clinical Trials<br>Adverse Reactions in Long-Term, Double-Blind, Placebo-Controlled Trials</p>
<p>The adverse reactions reported in a 26-week, double-blind trial comparing oral aripiprazole and placebo in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> were generally consistent with those reported in the short-term, placebo-controlled trials, except for a higher incidence of <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> [8% (12/153) for aripiprazole vs. 2% (3/153) for placebo]. In this study, the majority of the cases of <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> were of mild intensity (8/12 mild and 4/12 moderate), occurred early in therapy (9/12 ≤49 days), and were of limited duration (7/12 ≤10 days). <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> infrequently led to discontinuation (less than 1%) of aripiprazole. In addition, in a long-term (52-week), active-controlled study, the incidence of <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> was 5% (40/859) for aripiprazole. A similar profile was observed in a long-term monotherapy study and a long-term adjunctive study with lithium and valproate in bipolar disorder.</p>
<p>Other Adverse Reactions Observed During the Premarketing Evaluation of Aripiprazole</p>
<p>The following listing does not include reactions: 1) already listed in previous tables or elsewhere in labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have significant clinical implications, or 5) which occurred at a rate equal to or less than placebo.</p>
<p>Reactions are categorized by body system according to the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients:</p>
<p>Adults - Oral Administration </p>
<p>Blood and Lymphatic System Disorders: rare - <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span><br> 

<span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>: infrequent – <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, rare – <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span>, cardio-<span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4259490" conceptname="Cardiorespiratory failure">cardiopulmonary failure</span> <br>

<span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>: infrequent – <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>; rare - <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> <br>

<span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: infrequent - <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> <br>

General Disorders and Administration Site Conditions:frequent - <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>; infrequent – <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>; rare – face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> <br>

Hepatobiliary Disorders: rare - <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> <br>

<span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: rare- <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <br>

Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>, and Procedural Complications: infrequent– <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>; rare – <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> <br>

Investigations: frequent - <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>, infrequent - hepatic enzyme increased, blood glucose increased, blood lactate dehydrogenase increased, gamma glutamyl transferase increased; rare – <span class="product-label-link" type="condition" conceptid="4035688" conceptname="Increased prolactin level">blood prolactin increased</span>, blood urea increased, blood creatinine increased, blood bilirubin increased, <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">electrocardiogram QT prolonged</span>, <span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">glycosylated hemoglobin</span> increased <br>

Metabolism and Nutrition Disorders: frequent –<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>; infrequent - rare - <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> <br>

Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>: infrequent - <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="4097447" conceptname="Muscle tension">muscle tightness</span>; rare – <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="4310235" conceptname="Reduced mobility">mobility decreased</span> <br>

<span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: infrequent - <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>; rare – <span class="product-label-link" type="condition" conceptid="4143471" conceptname="Akinesia">akinesia</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">coordination abnormal</span>, speech disorder, <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">Grand Mal convulsion</span>; less than 1/10,000 patients - <span class="product-label-link" type="condition" conceptid="4181630" conceptname="Choreoathetosis">choreoathetosis</span> <br>

Psychiatric Disorders: infrequent – <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>; rare – <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">libido increased</span>, <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>, tic, <span class="product-label-link" type="condition" conceptid="4024763" conceptname="Homicidal thoughts">homicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>, <span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">sleep walking</span> <br>

Renal and Urinary Disorders: rare - <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span> <br>

Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>: infrequent - <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>; rare – <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynaecomastia</span>, <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">menstruation irregular</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> <br>

Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>: infrequent - <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> <br>

Skin and Subcutaneous Tissue Disorders: infrequent - <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>; rare - <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span><br> 

<span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>: infrequent – <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> 
</p>
<p>Pediatric Patients - Oral Administration</p>
<p>Most adverse events observed in the pooled database of 1,686 pediatric patients, aged 6 to 18 years, were also observed in the adult population. Additional adverse reactions observed in the pediatric population are listed below.</p>
<p><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span> infrequent - <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span> <br>

<span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: infrequent -<span class="product-label-link" type="condition" conceptid="4155891" conceptname="Dry tongue">tongue dry</span>, tongue spasm <br>

Investigations: frequent - blood insulin increased <br>

<span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: infrequent - <span class="product-label-link" type="condition" conceptid="4263778" conceptname="Sleeptalking">sleep talking</span> <br>

Renal and Urinary Disorders frequent – <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span> <br>
Skin and Subcutaneous Tissue Disorders: infrequent - <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span> 
</p>
<p><span class="Bold">Additional pediatric use information is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L877fd562-8902-4baf-ac1e-efe57ecb6690"></a><a name="section-7.2"></a><p></p>
<h2>  6.2 Postmarketing Experience
</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of aripiprazole. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to establish a causal relationship to drug exposure: occurrences of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>/<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or oropharyngeal spasm), and blood glucose fluctuation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Laf134b5e-afe1-48d1-bcbe-c7bc68dbf11e"></a><a name="section-8"></a><p></p>
<h1>  7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Lb43d95ca-9999-42d1-95cd-b25ebb72bfca"></a><a name="section-8.1"></a><p></p>
<h2>  7.1 Drugs Having Clinically Important Interactions with Aripiprazole
</h2>
<p class="First">
                 Table 14: Clinically Important Drug Interactions with Aripiprazole:
                </p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Concomitant Drug Name or Drug Class</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Clinical Rationale</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Clinical Recommendation</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin) or strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">The concomitant use of aripiprazole with strong CYP 3A4 or CYP2D6 inhibitors increased the exposure of aripiprazole compared to the use of aripiprazole alone [<span class="Italics">see CLINICAL PHARMACOLOGY (12.3)</span>].</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">With concomitant use of aripiprazole with a strong CYP3A4 inhibitor or CYP2D6 inhibitor, reduce the aripiprazole dosage [<span class="Italics">see DOSAGE AND ADMINISTRATION (2.7)</span>].</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Strong CYP3A4 Inducers (e.g., carbamazepine, rifampin)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">The concomitant use of aripiprazole and carbamazepine decreased the exposure of aripiprazole compared to the use of aripiprazole alone [<span class="Italics">see CLINICAL PHARMACOLOGY (12.3)</span>].</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">With concomitant use of aripiprazole with a strong CYP3A4 inducer, consider increasing the aripiprazole dosage [<span class="Italics">see DOSAGE AND ADMINISTRATION (2.7)</span>].</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Antihypertensive Drugs</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Due to its alpha adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Monitor blood pressure and adjust dose accordingly [<span class="Italics">see WARNINGS AND PRECAUTIONS (5.7)</span>].</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Benzodiazepines (e.g., lorazepam)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">The intensity of sedation was greater with the combination of oral aripiprazole and lorazepam as compared to that observed with aripiprazole alone. The <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> observed was greater with the combination as compared to that observed with lorazepam alone [<span class="Italics">see WARNINGS AND PRECAUTIONS (5.7)</span>]</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Monitor sedation and blood pressure. Adjust dose accordingly.</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lbded1096-594d-4eae-9711-a45978596311"></a><a name="section-8.2"></a><p></p>
<h2>  7.2 Drugs Having No Clinically Important Interactions with Aripiprazole
</h2>
<p class="First">Based on pharmacokinetic studies, no dosage adjustment of aripiprazole is required when administered concomitantly with famotidine, valproate, lithium, lorazepam.                
                </p>
<p>
                  In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin, escitalopram), or CYP3A4 (e.g., dextromethorphan)  when  co-administered  with  aripiprazole.   Additionally,  no  dosage adjustment is necessary for valproate, lithium, lamotrigine, lorazepam, or sertraline when co-administered with aripiprazole. [see CLINICAL PHARMACOLOGY (12.3)].
                </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="L23c10e91-403a-4336-a7ca-f54728ab672f"></a><a name="section-9"></a><p></p>
<h1>  8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="L717d7816-9b76-4727-bb69-96a6808d3a1a"></a><a name="section-9.1"></a><p></p>
<h2>  8.1 Pregnancy
</h2>
<p class="First"><span class="Bold">Teratogenic Effects</span></p>
<p><span class="Bold">Pregnancy Category C </span></p>
<p><span class="Italics">Pregnancy Exposure Registry</span></p>
<p>
                  There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aripiprazole during pregnancy. For more information contact the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.
                </p>
<p>
                  Risk Summary
                </p>
<p>
                 Neonates exposed to antipsychotic drugs (including aripiprazole) during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. Adequate and well controlled studies with aripiprazole have not been conducted in pregnant women. Animal reproduction studies were conducted with aripiprazole in rats and rabbits during organogenesis, and in rats during the pre-and post-natal period. Oral and intravenous aripiprazole administration during organogenesis in rats and/or rabbits at doses higher than the maximum recommended human dose (MRHD) produced <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>, decreased fetal weight, <span class="product-label-link" type="condition" conceptid="437655" conceptname="Undescended testicle">undescended testicles</span>, delayed skeletal ossification, skeletal abnormalities, and <span class="product-label-link" type="condition" conceptid="201061" conceptname="Diaphragmatic hernia">diaphragmatic hernia</span>. Oral and intravenous aripiprazole administration during the pre- and post-natal period in rats at doses higher than the maximum recommended human dose (MRHD) produced prolonged gestation, <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span>, decreased pup weight, and decreased pup survival. Administer aripiprazole during pregnancy only if the potential benefit justifies the potential risk to the fetus.
                </p>
<p>Clinical Considerations<br>Fetal/Neonatal Adverse Reactions</p>
<p>Extrapyramidal and/or withdrawal symptoms, including <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and <span class="product-label-link" type="condition" conceptid="434750" conceptname="Feeding difficulties and mismanagement">feeding disorder</span> have been reported in neonates who were exposed to antipsychotic drugs (including aripiprazole) during the third trimester of pregnancy. These symptoms have varied in severity. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. Monitor neonates for extrapyramidal and/or withdrawal symptoms.</p>
<p>Data<br>Animal Data</p>
<p>In animal studies, aripiprazole demonstrated developmental toxicity, including possible teratogenic effects in rats and rabbits.</p>
<p>Pregnant rats were treated with oral doses of 3, 10, and 30 mg/kg/day (1, 3, and 10 times the maximum recommended human dose [MRHD] on a mg/m2  basis) of aripiprazole during the period of organogenesis. Gestation was slightly prolonged at 30 mg/kg/day. Treatment at the high dose of 30 mg/kg/day caused a slight delay in fetal development (decreased fetal weight), undescended testes, and delayed skeletal ossification (also seen at  10 mg/kg/day).  There  were no adverse  effects  on  embryofetal or pup survival. Delivered offspring had decreased body weights (10 and 30 mg/kg/day), and increased incidences of hepatodiaphragmatic <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> and <span class="product-label-link" type="condition" conceptid="201061" conceptname="Diaphragmatic hernia">diaphragmatic hernia</span> at 30 mg/kg (the other dose groups were not examined for these findings). Postnatally, delayed vaginal opening  was  seen  at  10  and  30 mg/kg/day  and  impaired  reproductive  performance (decreased  fertility  rate,  corpora  lutea,  implants,  live  fetuses,  and  increased  post- implantation loss,  likely mediated through effects on  female offspring)  was  seen  at 30 mg/kg/day. Some maternal toxicity was seen at 30 mg/kg/day however, there was no evidence to suggest that these developmental effects were secondary to maternal toxicity.</p>
<p>In pregnant rats receiving aripiprazole injection intravenously (3, 9, and 27 mg/kg/day) during the period of organogenesis, decreased fetal weight and delayed skeletal ossification were seen at the highest dose where it also caused maternal toxicity.</p>
<p>Pregnant rabbits were treated with oral doses of 10, 30 , and 100 mg/kg/day (2 , 3, and 11 times human exposure at MRHD based on AUC and 6, 19 , and 65 times the MRHD based on mg/m2) of aripiprazole during the period of organogenesis. At the high dose of 100 mg/kg/day decreased maternal food consumption, and increased abortions were seen as well as increased fetal mortality, decreased fetal weight (also seen at 30 mg/kg/day), increased incidence of a  skeletal abnormality (fused sternebrae) (also  seen at 30 mg/kg/day).</p>
<p>In pregnant rabbits receiving aripiprazole injection intravenously (3, 10, and 30 mg/kg/day) during the period of organogenesis, the highest dose, which caused pronounced  maternal toxicity, resulted in decreased fetal  weight, increased fetal abnormalities (primarily skeletal), and decreased fetal skeletal ossification. The fetal no- effect dose was 10 mg/kg/day, which is 5 times the human exposure at the MRHD based on AUC and is 6 times the MRHD based on mg/m2.</p>
<p>In a study in which rats were treated peri- and post-natally with oral doses of 3, 10, and 30 mg/kg/day (1, 3, and 10 times the MRHD on a mg/m2 basis) of aripiprazole from gestation day 17  through day 21 postpartum, slight maternal toxicity, slightly prolonged gestation  an  increase  in  <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span>  and,  decreases  in  pup  weight  (persisting  into adulthood) and survival were seen at 30 mg/kg/day.</p>
<p>In  rats  receiving aripiprazole injection  intravenously (3,  8,  and  20 mg/kg/day)  from gestation day 6 through day 20 postpartum, an increase in <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> was seen at 8 and 20 mg/kg/day, and decreases in early postnatal pup weights and survival were seen at 20 mg/kg/day; these effects were seen in presence of   maternal toxicity. There were no effects on postnatal behavioral and reproductive development.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L779de4b8-85c1-4a33-8ee7-8f758eb6eecb"></a><a name="section-9.2"></a><p></p>
<h2>  8.3 Nursing Mothers
</h2>
<p class="First">Aripiprazole is present in human breast milk. Because of the potential for serious adverse reactions in nursing infants from aripiprazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L7e0d589e-083d-4d5b-9a57-a61091481628"></a><a name="section-9.3"></a><p></p>
<h2>  8.4 Pediatric Use
</h2>
<p class="First">
                  The pharmacokinetics of aripiprazole and dehydro-aripiprazole in pediatric patients, 10 to 17 years of age, were similar to those in adults after correcting for the differences in body weight [see CLINICAL PHARMACOLOGY (12.3)].
                </p>
<p>
                 <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>
                </p>
<p>
                 Safety and effectiveness in pediatric patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> were established in a 6-week, placebo-controlled clinical trial in 202 pediatric patients aged 13 to 17 years [see  DOSAGE AND ADMINISTRATION (2.1), ADVERSE REACTIONS (6.1), and CLINICAL STUDIES (14.1)]. Although maintenance efficacy in pediatric patients has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients.
                </p>
<p>
                  <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>
                </p>
<p>
				Safety and effectiveness in pediatric patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> were established in a 4-week, placebo-controlled clinical trial in 197 pediatric patients aged 10 to 17 years [see  DOSAGE AND ADMINISTRATION (2.2), ADVERSE REACTIONS (6.1), and CLINICAL STUDIES (14.2)]. Although maintenance efficacy in pediatric patients has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients.

                </p>
<p>
                  The efficacy of adjunctive aripiprazole with concomitant lithium or valproate in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes in pediatric patients has not been systematically evaluated. However, such efficacy and lack of <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between aripiprazole and lithium or valproate can be extrapolated from adult data, along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients.
                </p>
<p><span class="Bold"> AInformation describing a clinical study in which efficacy was not demonstrated in patients ages 6 to 17 years is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole). Additional pediatric use information in patients ages 6 to 18 years is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information</span></p>
<p><span class="Bold">Juvenile Animal Studies </span></p>
<p>Aripiprazole in juvenile rats caused mortality, CNS clinical signs, impaired memory and learning,  and  delayed  sexual  maturation when  administered at  oral  doses  of  10,  20, 40 mg/kg/day  from  weaning  (21  days  old)  through  maturity  (80  days old).  At 40 mg/kg/day, mortality, <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span>, splayed hind limbs, hunched posture, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> and other CNS signs were observed in both genders. In addition, delayed sexual maturation was observed in males. At all doses and in a dose-dependent manner, impaired memory and learning, increased motor activity, and histopathology changes in the pituitary (<span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>), adrenals (adrenocortical <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>), mammary glands (<span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and increased secretion), and female reproductive organs (vaginal mucification, endometrial <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, decrease in ovarian corpora lutea) were observed. The changes in female reproductive organs were considered secondary to the increase in prolactin serum levels. A No Observed Adverse Effect Level (NOAEL) could not be determined and, at the lowest tested dose of 10 mg/kg/day, there is no safety margin relative to the systemic exposures (AUC0-24) for aripiprazole or its major active metabolite in adolescents at the maximum recommended pediatric dose of 15 mg/day. All drug-related effects were reversible after a 2-month recovery period, and most of the drug effects in juvenile rats were also observed in adult rats from previously conducted studies.</p>
<p>Aripiprazole in juvenile dogs (2 months old) caused CNS clinical signs of <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, recumbency and limited use of hind limbs when administered orally for 6 months at 3, 10, 30 mg/kg/day. Mean body weight and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> were decreased up to 18% in females in all drug groups relative to control values. A NOAEL could not be determined and, at the lowest tested dose of 3 mg/kg/day, there is no safety margin relative to the systemic exposures (AUC0-24) for aripiprazole or its major active metabolite in adolescents at the maximum recommended pediatric dose of 15 mg/day. All drug-related effects were reversible after a 2-month recovery period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L75b4ba73-c218-4e4a-8084-3d72fee5b219"></a><a name="section-9.4"></a><p></p>
<h2>  8.5 Geriatric Use
</h2>
<p class="First">
                  No dosage adjustment is recommended for elderly patients [see also BOXED WARNING, WARNINGS AND PRECAUTIONS (5.1), and CLINICAL PHARMACOLOGY (12.3)].
                </p>
<p>
                 Of the 13,543 patients treated with oral aripiprazole in clinical trials, 1073 (8%) were ≥65 years old and 799 (6%) were ≥75 years old. Placebo-controlled studies of oral aripiprazole in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, or another indication did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
                </p>
<p>
                 Aripiprazole is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> associated with Alzheimer’s disease [see also BOXED WARNING and WARNINGS AND PRECAUTIONS (5.1)].
                </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Ld6aa4eac-288d-4ad8-a655-8b6c5c592a29"></a><a name="section-9.5"></a><p></p>
<h2>  8.6 CYP2D6 Poor Metabolizers
</h2>
<p class="First">Dosage adjustment is recommended in known CYP2D6 poor metabolizers due to high aripiprazole concentrations. Approximately 8% of Caucasians and 3–8% of Black/African Americans cannot metabolize CYP2D6 substrates and are classified as poor metabolizers (PM) [see DOSAGE AND ADMINISTRATION (2.7) and CLINICAL PHARMACOLOGY (12.3)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L7c15fca2-a86b-46d4-ac4d-524bf1f83f32"></a><a name="section-9.6"></a><p></p>
<h2>  8.7 Hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">No  dosage  adjustment for  aripiprazole is  required  on  the  basis  of  a  patient’s  hepatic function (mild to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, Child-Pugh score between 5 and 15), or renal function (mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, glomerular filtration rate between 15 and 90 mL/minute) [see CLINICAL PHARMACOLOGY (12.3)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L4a244d5b-f4cb-47e0-a683-1d33c7faa326"></a><a name="section-9.7"></a><p></p>
<h2>  8.8 Other Specific Populations
</h2>
<p class="First">
                 No dosage adjustment for aripiprazole is required on the basis of a patient’s sex, race, or smoking status [see CLINICAL PHARMACOLOGY (12.3)].
                </p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="La70a6898-7a8e-4049-964e-1d9934e83839"></a><a name="section-10"></a><p></p>
<h1>  9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="L3f139d10-ffce-41b9-98c8-fe7b6fb20625"></a><a name="section-10.1"></a><p></p>
<h2>  9.1 Controlled Substance
</h2>
<p class="First">Aripiprazole is not a controlled substance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Leb61eff8-c57e-4957-9abd-257077391ada"></a><a name="section-10.2"></a><p></p>
<h2>  9.2 Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>
</h2>
<p class="First">Aripiprazole has not been systematically studied in humans for its potential for abuse, tolerance, or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. In physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> studies in monkeys, withdrawal symptoms were observed upon abrupt cessation of dosing. While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of aripiprazole misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Laa2a4608-e870-4c03-8f2d-02f1d3b3cb2c"></a><a name="section-11"></a><p></p>
<h1>  10 OVERDOSAGE
</h1>
<p class="First">MedDRA terminology has been used to classify the adverse reactions.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Ld78ea063-fccd-4ce7-8c9b-ff3f3fa613db"></a><a name="section-11.1"></a><p></p>
<h2>  10.1 Human Experience
</h2>
<p class="First">In clinical trials and in postmarketing experience, adverse reactions of deliberate or accidental overdosage with oral aripiprazole have been reported worldwide. These include <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> with oral aripiprazole alone and in combination with other substances.  No fatality was reported with aripiprazole alone. The largest known dose with a known outcome involved acute ingestion of 1260 mg of oral aripiprazole (42 times the maximum recommended daily dose) by a patient who fully recovered. Deliberate or accidental overdosage was also reported in children (age 12 and younger) involving oral aripiprazole ingestions up to 195 mg with no fatalities.</p>
<p>Common adverse reactions (reported in at least 5% of all <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> cases) reported with oral aripiprazole overdosage (alone or in combination with other substances) include <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. Other clinically important signs and symptoms observed in one or more patients with aripiprazole <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> (alone or with other substances) include <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">blood creatine phosphokinase</span> increased, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span> prolonged, <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">QT prolonged</span>, <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">pneumonia aspiration</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L6926aa90-b240-4afd-a86f-3eecfc4d3b16"></a><a name="section-11.2"></a><p></p>
<h2>  10.2 Management of Overdosage
</h2>
<p class="First">No specific information is available on the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with aripiprazole. An electrocardiogram  should  be  obtained  in  case  of  overdosage  and  if  QT  interval prolongation is present, cardiac monitoring should be instituted. Otherwise, management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers.</p>
<p>Charcoal: In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of aripiprazole, an early charcoal administration may be useful in partially preventing the absorption of aripiprazole. Administration of 50 g of activated charcoal, one hour after a single 15 mg oral dose of aripiprazole, decreased the mean AUC and Cmax of aripiprazole by 50%.</p>
<p>Hemodialysis: Although there is no information on the effect of hemodialysis in treating an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with aripiprazole, hemodialysis is unlikely to be useful in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> management since aripiprazole is highly bound to plasma proteins.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Lc11b02b0-1988-46c3-9108-8da476074871"></a><a name="section-12"></a><p></p>
<h1>  11 DESCRIPTION
</h1>
<p class="First">Aripiprazole is a psychotropic drug that is available as Aripiprazole Oral Solution. Aripiprazole is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The empirical formula is C<span class="Sub">23</span>H<span class="Sub">27</span>C<span class="Sub">l2</span>N<span class="Sub">3</span>O<span class="Sub">2</span> and its molecular weight is 448.38.</p>
<p><img alt="Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7292c4c-e332-4ed4-9086-f130d223b6ae&amp;name=structure.jpg"></p>
<p>Aripiprazole Oral Solution is a clear, colorless to light yellow solution available in a concentration of 1 mg/mL. The inactive ingredients for this solution include butylated hydroxyanisole, methylparaben, phosphoric acid, propylene glycol, propylparaben, sodium hydroxide, sucralose, and purified water. The oral solution is orange flavored.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="L4de98e89-6b87-4152-ade7-f007deb7baee"></a><a name="section-13"></a><p></p>
<h1>  12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Lcb6a70b6-264b-4ca7-95a7-b9964d6d5136"></a><a name="section-13.1"></a><p></p>
<h2>  12.1 Mechanism of Action
</h2>
<p class="First">The mechanism of action of aripiprazole in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, is unknown. However, the efficacy of aripiprazole could be mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. Actions at receptors other than D2, 5-HT1A, and 5-HT2A may explain some of the other clinical effects of aripiprazole (e.g., the <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> observed with aripiprazole may be explained by its antagonist activity at adrenergic alpha1 receptors).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L6382cb4f-09ed-4ae6-badc-2ad7dc74ed80"></a><a name="section-13.2"></a><p></p>
<h2>  12.2 Pharmacodynamics
</h2>
<p class="First"><span><span>Aripiprazole exhibits high affinity for dopamine D</span><span class="Sub">
                          2
                        </span><span> and D</span><span class="Sub">
                          3
                        </span><span>, serotonin 5-HT</span><span class="Sub">
                          1
                        </span><span>A and 5-HT</span><span class="Sub">
                          2A
                        </span><span> receptors (K</span><span class="Sub">
                          i
                        </span><span> values of 0.34 nM, 0.8 nM, 1.7 nM, and 3.4 nM, respectively), moderate affinity for dopamine D</span><span class="Sub">
                          4
                        </span><span>, serotonin 5-HT</span><span class="Sub">
                          2C
                        </span><span> and 5-HT</span><span class="Sub">
                          7
                        </span><span>, alpha1-adrenergic and histamine H</span><span class="Sub">
                          1
                        </span><span> receptors (K</span><span class="Sub">
                          i
                        </span><span> values of 44 nM, 15 nM, 39 nM, 57 nM, and 61 nM, respectively), and moderate affinity for the serotonin reuptake site (Ki=98 nM). Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors (IC50&gt;1000 nM). Aripiprazole functions as a partial agonist at the dopamine D</span><span class="Sub">
                          2
                        </span><span> and the serotonin 5-HT</span><span class="Sub">
                          1A
                        </span><span> receptors, and as an antagonist at serotonin 5-HT</span><span class="Sub">
                          2A
                        </span><span> receptor.</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lf311c801-7044-444a-894a-e4cca1068e82"></a><a name="section-13.3"></a><p></p>
<h2>  12.3 Pharmacokinetics
</h2>
<p class="First">
                  Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole, and to a lesser extent, to its major metabolite, dehydro-aripiprazole, which has been shown to have affinities for D2 receptors similar to the parent drug and represents 40% of the parent drug exposure in plasma. The mean elimination half-lives are about 75 hours and 94 hours for aripiprazole and dehydro-aripiprazole, respectively. Steady-state concentrations are attained within 14 days of dosing for both active moieties. Aripiprazole accumulation is predictable from single-dose pharmacokinetics. At steady- state, the pharmacokinetics of aripiprazole is dose-proportional. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
                </p>
<p><span><span><span class="Bold">ORAL ADMINISTRATION</span></span></span></p>
<p><span class="Bold"><span><span>Absorption</span></span></span><span></span></p>
<p><span class="Italics">Tablet:</span>Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Aripiprazole can be administered with or without food. Administration of a 15 mg aripiprazole tablet with a standard high-fat meal did not significantly affect the Cmax or AUC of aripiprazole or its active metabolite, dehydro-aripiprazole, but delayed Tmax by 3 hours for aripiprazole and 12 hours for dehydro-aripiprazole.</p>
<p><span><span><span class="Italics">Oral Solution:</span> Aripiprazole is well absorbed when administered orally as the solution. At equivalent doses, the plasma concentrations of aripiprazole from the solution were higher than that from the tablet formulation. In a relative bioavailability study comparing the pharmacokinetics of 30 mg aripiprazole as the oral solution to 30 mg aripiprazole tablets in healthy subjects, the solution to tablet ratios of geometric mean Cmax and AUC values were 122% and 114%, respectively <span class="Italics">[see DOSAGE AND ADMINISTRATION </span><span class="Italics">(2.6)]</span>. The single-dose pharmacokinetics of aripiprazole were linear and dose-proportional between the doses of 5 mg to 30 mg.</span></span><span></span></p>
<p><span><span><span class="Bold">Distribution</span></span></span></p>
<p><span><span>The steady-state volume of distribution of aripiprazole following intravenous administration is high (404 L or 4.9 L/kg), indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and its major metabolite are greater than 99% bound to serum proteins, primarily to albumin. In healthy human volunteers administered 0.5 mg/day to 30 mg/day aripiprazole for 14 days, there was dose-dependent D</span><span class="Sub">
                              2
                            </span><span> receptor occupancy indicating brain penetration of aripiprazole in humans.</span></span><span></span></p>
<p><span><span><span class="Bold">Metabolism and Elimination</span></span></span></p>
<p><span><span>Aripiprazole is metabolized primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <span class="Italics">in vitro </span>studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalyzed by CYP3A4. Aripiprazole is the predominant drug moiety in the systemic circulation. At steady-state, dehydro-aripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma.</span></span></p>
<p><span>Following a single oral dose of [14C]-labeled aripiprazole, approximately 25% and 55% of the administered radioactivity was recovered in the urine and feces, respectively. Less than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.</span></p>
<p><span class="Italics">Drug Interaction Studies</span></p>
<p>Effects of other drugs on the exposures of aripiprazole and dehydro-aripiprazole are summarized in Figure 1 and Figure 2, respectively. Based on simulation, a 4.5-fold increase in mean Cmax and AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors. A 3-fold increase in mean Cmax and AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors.</p>
<p><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7292c4c-e332-4ed4-9086-f130d223b6ae&amp;name=figure1.jpg"></p>
<p><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7292c4c-e332-4ed4-9086-f130d223b6ae&amp;name=figure2.jpg"></p>
<p>The effects of aripiprazole on the exposures of other drugs are summarized in Figure 3. </p>
<p><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7292c4c-e332-4ed4-9086-f130d223b6ae&amp;name=figure3.jpg"></p>
<p>Studies in Specific Populations</p>
<p>Exposures of aripiprazole and dehydro-aripiprazole in specific populations are summarized in Figure 4 and Figure 5, respectively. In addition, in pediatric patients (10 to 17 years of age) administered with aripiprazole (20 mg to 30 mg), the body weight corrected aripiprazole clearance was similar to the adults.</p>
<p><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7292c4c-e332-4ed4-9086-f130d223b6ae&amp;name=figure4.jpg"></p>
<p><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7292c4c-e332-4ed4-9086-f130d223b6ae&amp;name=figure5.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="La9c91190-0c38-414c-9126-e827df369608"></a><a name="section-14"></a><p></p>
<h1>  13 NONCLINICAL TOXICOLOGY
</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="L2384b803-af7f-4679-9490-d79035204333"></a><a name="section-14.1"></a><p></p>
<h2>  13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First"><span><span><span class="Bold">Carcinogenesis</span></span></span></p>
<p><span>Lifetime carcinogenicity studies were conducted in ICR mice, Sprague-Dawley (SD) rats, and F344 rats. Aripiprazole was administered for 2 years in the diet at doses of 1, 3, 10, and 30 mg/kg/day to ICR mice and 1, 3, and 10 mg/kg/day to F344 rats (0.2 to 5 times and 0.3 to 3 times the maximum recommended human dose [MRHD] based on mg/m2, respectively). In addition, SD rats were dosed orally for 2 years at 10, 20, 40, and 60 mg/kg/day (3 to 19 times the MRHD based on mg/m2). Aripiprazole did not induce tumors in male mice or male rats. In female mice, the incidences of pituitary gland <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and mammary gland adenocarcinomas and adenoacanthomas were increased at dietary doses of 3 to 30 mg/kg/day (0.1 to 0.9 times human exposure at MRHD based on AUC and 0.5 to 5 times the MRHD based on mg/m2). In female rats, the incidence of mammary gland fibroadenomas was increased at a dietary dose of 10 mg/kg/day (0.1 times human exposure at MRHD based on AUC and 3 times the MRHD based on mg/m2); and the incidences of adrenocortical carcinomas and combined adrenocortical <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>/carcinomas were increased at an oral dose of 60 mg/kg/day (14 times human exposure at MRHD based on AUC and 19 times the MRHD based on mg/m2).<br><br>Proliferative changes in the pituitary and mammary gland of rodents have been observed following chronic administration of other antipsychotic agents and are considered prolactin-mediated. Serum prolactin was not measured in the aripiprazole carcinogenicity studies. However, increases in serum prolactin levels were observed in female mice in a 13-week dietary study at the doses associated with mammary gland and pituitary tumors. Serum prolactin was not increased in female rats in 4-week and 13-week dietary studies at the dose associated with mammary gland tumors. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown.
					
					
					
					
					
					</span></p>
<p><span></span></p>
<p><span><span><span class="Bold">Mutagenesis</span></span></span></p>
<p><span><span>TThe mutagenic potential of aripiprazole was tested in the in vitro bacterial reverse- mutation assay, the in vitro bacterial DNA repair assay, the in vitro forward gene mutation assay in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells, the in vitro chromosomal aberration assay in Chinese hamster lung (CHL) cells, the in vivo micronucleus assay in mice, and the unscheduled DNA synthesis assay in rats. Aripiprazole and a metabolite (2,3-DCPP) were clastogenic in the in vitro chromosomal aberration assay in CHL cells with and without metabolic activation. The metabolite, 2,3-DCPP, produced increases in numerical aberrations in the in vitro assay in CHL cells in the absence of metabolic activation. A positive response was obtained in the in vivo micronucleus assay in mice; however, the response was due to a mechanism not considered relevant to humans.</span></span></p>
<p><span></span></p>
<p><span><span><span class="Bold">Impairment of Fertility</span></span></span></p>
<p><span>
                    Female rats were treated with oral doses of 2, 6, and 20 mg/kg/day (0.6, 2, and 6 times the maximum recommended human dose [MRHD] on a mg/m2 basis) of aripiprazole from 2 weeks prior to mating through day 7 of gestation. Estrus cycle irregularities and increased corpora lutea were seen at all doses, but no impairment of fertility was seen. Increased pre-implantation loss was seen at 6 and 20 mg/kg/day and decreased fetal weight was seen at 20 mg/kg/day.
                  </span></p>
<p><span></span></p>
<p><span>
                    Male rats were treated with oral doses of 20, 40, and 60 mg/kg/day (6, 13, and 19 times the MRHD on a mg/m2 basis) of aripiprazole from 9 weeks prior to mating through mating. Disturbances in spermatogenesis were seen at 60 mg/kg and prostate <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> was seen at 40 and 60 mg/kg, but no impairment of fertilitywas seen.
                  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lc8765dc4-71d2-457b-bd0b-4bdae8244802"></a><a name="section-14.2"></a><p></p>
<h2>  13.2 Animal Toxicology and/or Pharmacology
</h2>
<p class="First"><span>
                    Aripiprazole produced <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal degeneration</span> in albino rats in a 26-week chronic toxicity study at a dose of 60 mg/kg and in a 2-year carcinogenicity study at doses of 40 and 60 mg/kg. The 40 and 60 mg/kg/day doses are 13 and 19 times the maximum recommended human dose (MRHD) based on mg/m2 and 7 to 14 times human exposure at MRHD based on AUC. Evaluation of the retinas of albino mice and of monkeys did not reveal evidence of <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal degeneration</span>. Additional studies to further evaluate the mechanism have not been performed. The relevance of this finding to human risk is unknown.
                  </span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="L13573490-3fed-4e50-9ecb-80b2220f4e28"></a><a name="section-15"></a><p></p>
<h1>  14 CLINICAL STUDIES
</h1>
<p class="First">Efficacy  of  the  oral  formulations  of  aripiprazole  was  established  in  the following adequate and well-controlled trials:</p>
<p>•	Four short-term trials and one maintenance trial in adult patients and one short-term trial in adolescents (ages 13-17) with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (14.1)<br>
•	Four short-term monotherapy trials and one 6-week adjunctive trial in adult patients and one short-term monotherapy trial in pediatric patients (ages 10-17) with <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes (14.2)<br>
•	One maintenance monotherapy trial and in one maintenance adjunctive trial in adult patients with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (14.2)
</p>
<p><span class="Bold">Additional pediatric use information is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="L6c6a5ee7-a0ad-4916-9394-57fef2effc87"></a><a name="section-15.1"></a><p></p>
<h2>  14.1 <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>
</h2>
<p class="First"><span><span><span class="Bold">Adults</span></span></span></p>
<p>
                 The efficacy of aripiprazole in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was evaluated in five short- term (4-week and 6-week), placebo-controlled trials of acutely relapsed inpatients who predominantly met DSM-III/IV criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. Four of the five trials were able to distinguish aripiprazole from placebo, but one study, the smallest, did not. Three of these studies also included an active control group consisting of either risperidone (one trial) or haloperidol (two trials), but they were not designed to allow for a comparison of aripiprazole and the active comparators.
                </p>
<p>
                  In the four positive trials for aripiprazole, four primary measures were used for assessing psychiatric signs  and symptoms. Efficacy was  evaluated using the total score on  the Positive and Negative Syndrome Scale (PANSS). The PANSS is a 30 item scale that measures   positive   symptoms   of   <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>  (7   items),   negative   symptoms   of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (7 items), and general psychopathology (16 items), each rated on a scale of 1 (absent) to 7 (extreme); total PANSS scores range from 30 to 210. The Clinical Global Impression (CGI) assessment reflects the impression of a skilled observer, fully familiar with the manifestations of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, about the overall clinical state of the patient.
                </p>
<p>
                  In  a  4-week trial (n=414) comparing two  fixed doses  of  aripiprazole (15  or 30 mg/day) to placebo, both doses of aripiprazole were superior to placebo in the PANSS total score (Study 1 in Table 15), PANSS positive subscale, and CGI- severity score.  In  addition,  the  15 mg  dose  was  superior to  placebo in  the PANSS negative subscale.
                </p>
<p>
                 In  a  4-week trial (n=404) comparing two  fixed doses  of  aripiprazole (20  or 30 mg/day) to placebo, both doses of aripiprazole were superior to placebo in the PANSS total score (Study 2 in Table 15), PANSS positive subscale, PANSS negative subscale, and CGI-severity score.
                </p>
<p>
                 In a 6-week trial (n=420) comparing three fixed doses of aripiprazole (10, 15, or 20 mg/day) to placebo, all three doses of aripiprazole were superior to placebo in the PANSS total score (Study 3 in Table 15), PANSS positive subscale, and the PANSS negative subscale.
                </p>
<p>
                  In a 6-week trial (n=367) comparing three fixed doses of aripiprazole (2, 5, or 10 mg/day) to placebo, the 10 mg dose of aripiprazole was superior to placebo in the PANSS total score (Study 4 in Table 15), the primary outcome measure of the study. The 2 and 5 mg doses did not demonstrate superiority to placebo on the primary outcome measure.
                </p>
<p>
                 Thus, the efficacy of 10, 15, 20, and 30 mg daily doses was established in two studies for each dose. Among these doses, there was no evidence that the higher dose groups offered any advantage over the lowest dose group of these studies.
                </p>
<p>
                 An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, gender, or race.
                </p>
<p>
                  A longer-term trial enrolled 310 inpatients or outpatients meeting DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>  who  were,  by  history,  symptomatically  stable  on  other  antipsychotic medications for periods of 3 months or longer. These patients were discontinued from their antipsychotic medications and randomized to aripiprazole 15 mg/day or placebo for up to 26 weeks of observation for relapse. Relapse during the double-blind phase was defined as CGI-Improvement score of ≥5 (minimally worse), scores ≥5 (moderately severe) on the <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> or uncooperativeness items of the PANSS, or ≥20% increase in the PANSS total score. Patients receiving aripiprazole 15 mg/day experienced a significantly longer time to relapse over the subsequent 26 weeks compared to those receiving placebo (Study 5 in Figure 6).
                </p>
<p>
                  Pediatric Patients
                </p>
<p>
                  The efficacy of aripiprazole in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in pediatric patients (13 to 17 years of age) was evaluated in one 6-week, placebo-controlled trial of outpatients who met DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and had a PANSS score ≥70 at baseline. In this trial (n=302) comparing two fixed doses of aripiprazole (10 or 30 mg/day) to placebo, aripiprazole was titrated starting from 2 mg/day to the target dose in 5 days in the 10 mg/day treatment arm and in 11 days in the 30 mg/day treatment arm. Both doses of aripiprazole were superior to placebo in the PANSS total score (Study 6 in Table 15), the primary outcome measure of the study. The 30 mg/day dosage was not shown to be more efficacious than the 10 mg/day dose. Although maintenance efficacy in pediatric patients has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients.
                </p>
<p><span class="Bold">Table 15: <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> Studies</span></p>
<table width="100%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="19%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Difference (drug minus placebo) in least-squares mean change from baseline.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>Doses statistically significantly superior to placebo.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"><p class="First"><span class="Bold">Study Number</span></p></td>
<td class="Lrule Rrule Toprule"><p class="First"><span class="Bold">Treatment Group</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Primary Efficacy Measure: PANSS</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Mean Baseline Score (SD) </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">LS Mean Change from Baseline (SE) </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Placebo-subtracted Difference</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a><span class="Bold"> (95% CI) </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="3"><p class="First">Study 1</p></td>
<td><p class="First">Aripiprazole (15 mg/day)<a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a></p></td>
<td align="center"><p class="First">98.5 (17.2)</p></td>
<td align="center"><p class="First">-15.5 (2.40)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">-12.6 (-18.9, -6.2)</p></td>
</tr>
<tr>
<td><p class="First">Aripiprazole (30 mg/day)<a href="#footnote-9" class="Sup">†</a></p></td>
<td align="center"><p class="First">99.0 (19.2)</p></td>
<td align="center"><p class="First">-11.4 (2.39)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">-8.5 (-14.8, -2.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">100.2 (16.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-2.9 (2.36)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">--</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="3"><p class="First">Study 2</p></td>
<td><p class="First">Aripiprazole (20 mg/day)<a href="#footnote-9" class="Sup">†</a></p></td>
<td align="center"><p class="First">92.6 (19.5)</p></td>
<td align="center"><p class="First">-14.5 (2.23)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">-9.6 (-15.4, -3.8)</p></td>
</tr>
<tr>
<td><p class="First">Aripiprazole (30 mg/day)<a href="#footnote-9" class="Sup">†</a></p></td>
<td align="center"><p class="First">94.2 (18.5)</p></td>
<td align="center"><p class="First">-13.9 (2.24)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">-9.0 (-14.8, -3.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">94.3 (18.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-5.0 (2.17)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">--</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="4"><p class="First">Study 3</p></td>
<td><p class="First">Aripiprazole (10 mg/day)<a href="#footnote-9" class="Sup">†</a></p></td>
<td align="center"><p class="First">92.7 (19.5)</p></td>
<td align="center"><p class="First">-15.0 (2.38)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">-12.7 (-19.00, -6.41)</p></td>
</tr>
<tr>
<td><p class="First">Aripiprazole (15 mg/day)<a href="#footnote-9" class="Sup">†</a></p></td>
<td align="center"><p class="First">93.2 (21.6)</p></td>
<td align="center"><p class="First">-11.7 (2.38)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">-9.4 (-15.71, -3.08)</p></td>
</tr>
<tr>
<td><p class="First">Aripiprazole (20 mg/day)<a href="#footnote-9" class="Sup">†</a></p></td>
<td align="center"><p class="First">92.5 (20.9)</p></td>
<td align="center"><p class="First">-14.4 (2.45)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">-12.1 (-18.53, -5.68)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">92.3 (21.8)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-2.3 (2.35)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">--</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="4"><p class="First">Study 4</p></td>
<td><p class="First">Aripiprazole (2 mg/day) </p></td>
<td align="center"><p class="First">90.7 (14.5)</p></td>
<td align="center"><p class="First">-8.2 (1.90)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">-2.9 (-8.29, 2.47)</p></td>
</tr>
<tr>
<td><p class="First">Aripiprazole (5 mg/day) </p></td>
<td align="center"><p class="First">92.0 (12.6)</p></td>
<td align="center"><p class="First">-10.6 (1.93)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">-5.2 (-10.7, 0.19)</p></td>
</tr>
<tr>
<td><p class="First">Aripiprazole (10 mg/day)<a href="#footnote-9" class="Sup">†</a></p></td>
<td align="center"><p class="First">90.0 (11.9)</p></td>
<td align="center"><p class="First">-11.3 (1.88)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">-5.9 (-11.3, -0.58)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">90.8 (13.3)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-5.3 (1.97)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">--</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="3"><p class="First">Study 6 (Pediatric, 13 to 17 years)</p></td>
<td><p class="First">Aripiprazole (10 mg/day)<a href="#footnote-9" class="Sup">†</a></p></td>
<td align="center"><p class="First">93.6 (15.7)</p></td>
<td align="center"><p class="First">-26.7 (1.91)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">-5.5 (-10.7, -0.21)</p></td>
</tr>
<tr>
<td><p class="First">Aripiprazole (30 mg/day)<a href="#footnote-9" class="Sup">†</a></p></td>
<td align="center"><p class="First">94.0 (16.1)</p></td>
<td align="center"><p class="First">-28.6 (1.92)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">-7.4 (-12.7, -2.13)</p></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">94.6 (15.6)</p></td>
<td align="center"><p class="First">-21.2 (1.93)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">--</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="5"><p class="First">SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.</p></td></tr>
</tbody>
</table>
<p><img alt="Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7292c4c-e332-4ed4-9086-f130d223b6ae&amp;name=figure6.jpg"></p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lfbfd98b2-b3f3-4ec2-9c28-2a750802fc4b"></a><a name="section-15.2"></a><p></p>
<h2>  14.2 Bipolar Disorder
</h2>
<p class="First"><span class="Bold"><span><span>Acute Treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> and Mixed Episodes</span></span></span></p>
<p><span></span></p>
<p><span class="Bold"><span class="Italics"><span><span>Adults</span></span></span></span></p>
<p><span></span></p>
<p><span><span><span class="Bold">Monotherapy</span></span></span></p>
<p><span><span>The efficacy of aripiprazole as monotherapy in the acute treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> was established in four 3-week, placebo-controlled trials in hospitalized patients who met the DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> with <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes. These studies included patients with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features and two of the studies also included patients with or without a rapid-cycling course.</span></span></p>
<p><span></span></p>
<p><span><span>The primary instrument used for assessing <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms was the Young <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Rating Scale (Y-MRS), an 11-item clinician-rated scale traditionally used to assess the degree of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptomatology (<span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, disruptive/<span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, sleep, <span class="product-label-link" type="condition" conceptid="4304866" conceptname="Elevated mood">elevated mood</span>, speech, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">increased activity</span>, sexual interest, language/thought disorder, thought content, appearance, and insight) in a range from 0 (no <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> features) to 60 (maximum score). A key secondary instrument included the Clinical Global Impression - Bipolar (CGI-BP) Scale.</span></span></p>
<p><span></span></p>
<p><span><span>In the four positive, 3-week, placebo-controlled trials (n=268; n=248; n=480; n=485) which evaluated aripiprazole in a range of 15 mg to 30 mg, once daily (with a starting dose of 30 mg/day in two studies and 15 mg/day in two studies), aripiprazole was superior to placebo in the reduction of Y-MRS total score (Studies 1-4 in Table 16) and CGI-BP Severity of Illness score (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>). In the two studies with a starting dose of 15 mg/day, 48% and 44% of patients were on 15 mg/day at endpoint. In the two studies with a starting dose of 30 mg/day, 86% and 85% of patients were on 30 mg/day at endpoint.</span></span></p>
<p><span></span></p>
<p><span><span><span class="Bold">Adjunctive Therapy</span></span></span></p>
<p><span><span>The efficacy of adjunctive aripiprazole with concomitant lithium or valproate in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes was established in a 6-week, placebo-controlled study (n=384) with a 2-week lead-in mood stabilizer monotherapy phase in adult patients who met DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>. This study included patients with <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes and with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features.</span></span></p>
<p><span></span></p>
<p><span><span>Patients were initiated on open-label lithium (0.6 mEq/L to 1.0 mEq/L) or valproate (50 μg/mL to 125 μg/mL) at therapeutic serum levels, and remained on stable doses for 2 weeks. At the end of 2 weeks, patients demonstrating inadequate response (Y-MRS total score ≥16 and ≤25% improvement on the Y-MRS total score) to lithium or valproate were randomized to receive either aripiprazole (15 mg/day or an increase to 30 mg/day as early as day 7) or placebo as adjunctive therapy with open-label lithium or valproate. In the 6-week, placebo-controlled phase, adjunctive aripiprazole starting at 15 mg/day with concomitant lithium or valproate (in a therapeutic range of 0.6 mEq/L to 1.0 mEq/L or 50 μg/mL to 125 μg/mL, respectively) was superior to lithium or valproate with adjunctive placebo in the reduction of the Y-MRS total score (Study 5 in Table 16) and CGI-BP Severity of Illness score (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>). Seventy-one percent of the patients coadministered valproate and 62% of the patients coadministered lithium were on 15 mg/day at 6-week endpoint.</span></span></p>
<p><span></span></p>
<p><span><span><span class="Bold"><span class="Italics">Pediatric Patients</span></span></span></span></p>
<p><span><span>The efficacy of aripiprazole in the treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> in pediatric patients (10 to 17 years of age) was evaluated in one 4-week, placebo-controlled trial (n=296) of outpatients who met DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features and had a Y-MRS score ≥20 at baseline. This double-blind, placebo-controlled trial compared two fixed doses of aripiprazole (10 mg/day or 30 mg/day) to placebo. The aripiprazole dose was started at 2 mg/day, which was titrated to 5 mg/day after 2 days, and to the target dose in 5 days in the 10 mg/day treatment arm, and in 13 days in the 30 mg/day treatment arm. Both doses of aripiprazole were superior to placebo in change from baseline to week 4 on the Y-MRS total score.(Study 6 in Table 16).</span></span></p>
<p><span class="Bold">Table 16: Bipolar Studies</span></p>
<table width="100%">
<col width="17%">
<col width="20%">
<col width="20%">
<col width="22%">
<col width="21%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>Difference (drug minus placebo) in least-squares mean change from baseline.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">†</a></dt>
<dd>Doses statistically significantly superior to placebo.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"><p class="First"><span class="Bold">Study Number</span></p></td>
<td class="Lrule Rrule Toprule"><p class="First"><span class="Bold">Treatment Group</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Primary Efficacy Measure: Y-MRS</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Mean Baseline Score (SD) </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">LS Mean Change from Baseline (SE) </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Placebo-subtracted Difference</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a><span class="Bold"> (95% CI) </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Study 1</p></td>
<td><p class="First">Aripiprazole (30 / 15 mg/day)<a href="#footnote-9" class="Sup">†</a></p></td>
<td><p class="First">29.0 (5.9) </p></td>
<td><p class="First">-12.52 (1.05) </p></td>
<td class="Lrule Rrule Toprule"><p class="First">-5.33 (-7.90, -2.76) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule"><p class="First">28.5 (4.6) </p></td>
<td class="Botrule Lrule Rrule"><p class="First">-7.19 (1.07) </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">--</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Study 2</p></td>
<td><p class="First">Aripiprazole (30 / 15 mg/day)<a name="footnote-reference-11" href="#footnote-11" class="Sup">†</a></p></td>
<td><p class="First">27.8 (5.7) </p></td>
<td><p class="First">-8.15 (1.23) </p></td>
<td class="Lrule Rrule Toprule"><p class="First">-4.80 (-7.80, -1.80) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule"><p class="First">29.1 (6.9) </p></td>
<td class="Botrule Lrule Rrule"><p class="First">-3.35 (1.22) </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">--</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Study 3</p></td>
<td><p class="First">Aripiprazole (15 to 30 mg/day)<a href="#footnote-11" class="Sup">†</a></p></td>
<td><p class="First">28.5 (5.6) </p></td>
<td><p class="First">-12.64 (0.84) </p></td>
<td class="Lrule Rrule Toprule"><p class="First">-3.63 (-5.75 , -1.51) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule"><p class="First">28.9 (5.9) </p></td>
<td class="Botrule Lrule Rrule"><p class="First">9.01 (0.81) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">--</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Study 4</p></td>
<td><p class="First">Aripiprazole (15 to 30 mg/day)<a href="#footnote-11" class="Sup">†</a></p></td>
<td><p class="First">28.0 (5.8) </p></td>
<td><p class="First">-11.98 (0.80) </p></td>
<td class="Lrule Rrule Toprule"><p class="First">-2.28 (-4.44 , -0.11) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule"><p class="First">28.3 (5.8) </p></td>
<td class="Botrule Lrule Rrule"><p class="First">-9.70 (0.83) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">--</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Study 5</p></td>
<td><p class="First">Aripiprazole (15 or 30 mg/day)<a href="#footnote-11" class="Sup">†</a></p></td>
<td><p class="First">23.2 (5.7) </p></td>
<td><p class="First">-13.31 (0.50) </p></td>
<td class="Lrule Rrule Toprule"><p class="First">-2.62 (-4.29, -0.95) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">+ Lithium/Valproate Placebo + Lithium/Valproate </p></td>
<td class="Botrule Lrule Rrule"><p class="First">23.0 (4.9) </p></td>
<td class="Botrule Lrule Rrule"><p class="First">-10.70 (0.69) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">--</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="3"><p class="First">Study 6 (Pediatric, 10 to 17 years)</p></td>
<td><p class="First">Aripiprazole (10 mg/day)<a href="#footnote-11" class="Sup">†</a></p></td>
<td><p class="First">29.8 (6.5) </p></td>
<td><p class="First">-14.2 (0.89) </p></td>
<td class="Lrule Rrule Toprule"><p class="First">-5.99 (-8.49, -3.50) </p></td>
</tr>
<tr>
<td><p class="First">Aripiprazole (30 mg/day)<a href="#footnote-11" class="Sup">†</a></p></td>
<td><p class="First">29.5 (6.3) </p></td>
<td><p class="First">-16.5 (0.87) </p></td>
<td class="Lrule Rrule"><p class="First">-8.26 (-10.7, -5.77) </p></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td><p class="First">30.7 (6.8) </p></td>
<td><p class="First">-8.2 (0.91) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">--</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="5"><p class="First">SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.</p></td></tr>
</tbody>
</table>
<p><span class="Bold"><span><span>Maintenance Treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span></span></span></span></p>
<p><span></span></p>
<p><span><span><span class="Bold"><span class="Italics">Monotherapy Maintenance Therapy</span></span></span></span></p>
<p>
                  A maintenance trial was conducted in adult patients meeting DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> with a recent <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episode who had been stabilized on open-label aripiprazole and who had maintained a clinical response for at least 6 weeks. The first phase  of  this  trial  was  an  open-label  stabilization  period  in  which  inpatients  and outpatients were clinically stabilized and then maintained on open-label aripiprazole (15 or 30 mg/day, with a starting dose of 30 mg/day) for at least 6 consecutive weeks. One hundred sixty-one outpatients were then randomized in a double-blind fashion, to either the same dose of aripiprazole they were on at the end of the stabilization and maintenance period or placebo and were then monitored for <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or depressive relapse. During the randomization  phase,  aripiprazole was  superior  to  placebo  on  time  to  the  number  of combined affective relapses (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> plus depressive), the primary outcome measure for this study (Study 7 in Figure 7). A total of 55 mood events were observed during the double-blind treatment phase. Nineteen were from the aripiprazole group and 36 were from the placebo group. The number of observed <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> in the aripiprazole group (6) were fewer than that in the placebo group (19), while the number of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> in the aripiprazole group (9) was similar to that in the placebo group (11).
                </p>
<p>
                  An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age and gender; however, there were insufficient numbers of patients in each of the ethnic groups to adequately assess inter-group differences.
                </p>
<p><img alt="Figure 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7292c4c-e332-4ed4-9086-f130d223b6ae&amp;name=figure7.jpg"></p>
<p><span><span><span class="Bold"><span class="Italics">Adjunctive Maintenance Therapy</span></span></span></span></p>
<p>
                  An adjunctive maintenance trial was conducted in adult patients meeting DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> with a recent <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episode. Patients were initiated on open-label lithium (0.6 to 1.0 mEq/L) or valproate (50 to 125 μg/mL) at therapeutic serum levels, and remained on stable doses for 2 weeks. At the end of 2 weeks, patients demonstrating inadequate response (Y-MRS total score ≥16 and ≤35% improvement on the Y-MRS total score) to lithium or valproate received aripiprazole with a starting dose of 15 mg/day with the option to increase to 30 mg or reduce to 10 mg as early as day 4, as adjunctive therapy with open-label lithium or valproate. Prior to randomization, patients on the combination of single-blind aripiprazole and lithium or valproate were required to maintain stability (Y-MRS and MADRS total scores ≤12) for 12 consecutive weeks. Three hundred thirty-seven patients were then randomized in a double-blind fashion, to either the same dose of aripiprazole they were on at the end of the stabilization period or placebo plus lithium or valproate and were then monitored for <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>, mixed, or depressive relapse for a maximum of 52 weeks. Aripiprazole was superior to placebo on the primary endpoint, time from randomization to relapse to any mood event (Study 8 in Figure 8). A mood event was defined as hospitalization for a <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>, mixed, or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span>, study discontinuation due to lack of efficacy accompanied by Y-MRS score &gt;16 and/or a MADRS &gt;16, or an SAE of worsening disease accompanied by Y-MRS score
&gt;16 and/or a MADRS &gt;16. A total of 68 mood events were observed during the double- blind treatment phase. Twenty-five were from the aripiprazole group and 43 were from the placebo group. The number of observed <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> in the aripiprazole group (7) were fewer than that in the placebo group (19), while the number of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> in the aripiprazole group (14) was similar to that in the placebo group (18). The Kaplan-Meier curves of the time from randomization to relapse to any mood event during the 52-week, double-blind treatment phase for aripiprazole and placebo groups are shown in Figure 8.

                </p>
<p><img alt="Figure 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7292c4c-e332-4ed4-9086-f130d223b6ae&amp;name=figure8.jpg"></p>
<p>
                  An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age and gender; however, there were insufficient numbers of patients in each of the ethnic groups to adequately assess inter-group differences.
                </p>
<p><span class="Bold">Additional pediatric use information is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="L770e9940-e19e-4096-901f-aae6a039cf8a"></a><a name="section-16"></a><p></p>
<h1>  16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="L98004a01-e8d7-4314-9619-837c836b68de"></a><a name="section-16.1"></a><p></p>
<h2>  16.1 How Supplied
</h2>
<p class="First"><span><span>Aripiprazole Oral Solution (1 mg/mL) is supplied in child-resistant bottles along with a calibrated oral dosing cup. Aripiprazole Oral Solution is available as follows:</span></span></p>
<p><span></span></p>
<ul>
<li><span><span>150 mL bottle</span></span></li>
<li><span><span>237 mL bottle</span></span></li>
</ul>
<p><span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L36704041-4da0-482d-91ed-e77a2b3fcaae"></a><a name="section-16.2"></a><p></p>
<h2>  16.2 Storage
</h2>
<p class="First"><span><span><span class="Bold">Oral Solution</span></span></span></p>
<p><span><span>Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Opened bottles of Aripiprazole Oral Solution can be used for up to 6 months after opening, but not beyond the expiration date on the bottle. The bottle and its contents should be discarded after the expiration date.</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="L79eb4112-98d4-49d8-a388-1c930e0759ae"></a><a name="section-17"></a><p></p>
<h1>  17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First"> See Medication Guide</p>
<p>Discuss the following issues with patients prescribed Aripiprazole:</p>
<p>Clinical Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</p>
<p>Patients, their families, and their  caregivers should  be  encouraged to  be  alert  to  the emergence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>,  impulsivity,  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>  (psychomotor  <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>),  <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>,  <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, other  unusual  changes  in  behavior,  worsening  of  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>,  and  suicidal  ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient’s prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and  indicate  a  need  for  very  close  monitoring  and  possibly  changes  in  the medication [see WARNINGS AND PRECAUTIONS (5.2)].</p>
<p>Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with aripiprazole and should counsel them  in its appropriate  use.  A patient Medication Guide including information about “Antidepressant Medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>  and other  Serious Mental Illness, and Suicidal Thoughts or Actions? is available for aripiprazole. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. It should be noted that aripiprazole oral solution is not approved as a single agent for treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and has not been evaluated in pediatric major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>.</p>
<p>Interference with Cognitive and Motor Performance</p>
<p>Because aripiprazole may have the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that aripiprazole therapy does not affect them adversely [see WARNINGS AND PRECAUTIONS (5.9)].</p>
<p>Nursing</p>
<p>Advise patients that breastfeeding is not recommended with aripiprazole treatment because of the potential for serious adverse reactions in a nursing infant [see USE IN SPECIFIC POPULATIONS (8.3)].</p>
<p>Concomitant Medication</p>
<p>Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions [see  DRUG INTERACTIONS (7)].</p>
<p>Heat Exposure and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></p>
<p>Patients should be advised regarding appropriate care in avoiding overheating and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> [see WARNINGS AND PRECAUTIONS (5.10)].</p>
<p>All registered trademarks are the property of their respective owners. </p>
<p>Manufactured by:<br>Silarx Pharmaceuticals, Inc.<br>Carmel, NY 10512 USA
</p>
</div>
<div class="Section" data-sectionCode="68498-5">
<a name="Lba0725c2-3084-4f4b-b8c9-01209d53ed9e"></a><a name="section-18"></a><p></p>
<h1>  MEDICATION GUIDE
</h1>
<p class="First"><span><span><span class="Bold">Aripiprazole (</span><span class="Bold">air-eh-PIP-rah-zole) </span><span class="Bold">Oral Solution</span></span></span></p>
<p><span class="Bold"><span></span></span></p>
<p><span><span>Read this Medication Guide before you start taking Aripiprazole Oral Solution and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment.</span></span></p>
<p><span></span><span><span class="Bold">What</span><span class="Bold"></span><span class="Bold">is</span><span class="Bold"></span><span class="Bold">the most important information I should know about Aripiprazole?</span></span></p>
<p><span class="Bold"><span></span></span><span>(For other side effects, also see “<span class="Bold">What</span><span class="Bold"> are the possible side effects of Aripiprazole?</span>?).</span></p>
<p><span></span><span>Serious side effects may happen when you take Aripiprazole Oral Solution, including:</span></p>
<ul>
<li><span><span class="Bold">Increased</span><span class="Bold"></span><span class="Bold">risk</span><span class="Bold"></span><span class="Bold">of</span><span class="Bold"></span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span><span class="Bold"></span><span class="Bold">in</span><span class="Bold"></span><span class="Bold">elderly</span><span class="Bold"></span><span class="Bold">patients</span><span class="Bold"></span><span class="Bold">with</span><span class="Bold"></span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related</span><span class="Bold"></span><span class="Bold"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>:</span><span class="Bold"></span>Medicines like aripiprazole can raise the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in elderly people who have lost touch with reality (<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>) due to <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span> (<span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>). Aripiprazole is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.</span></li>
<li><span><span class="Bold">Risk</span><span class="Bold"></span><span class="Bold">of</span><span class="Bold"></span><span class="Bold">suicidal</span><span class="Bold"></span><span class="Bold">thoughts</span><span class="Bold"></span><span class="Bold">or</span><span class="Bold"></span><span class="Bold">actions:</span><span class="Bold"></span>Antidepressant medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other serious mental illnesses, and suicidal thoughts or actions:</span></li>
</ul>
<ol>
<li><span><span class="Bold">Antidepressant</span><span class="Bold"></span><span class="Bold">medicines</span><span class="Bold"></span><span class="Bold">may</span><span class="Bold"></span><span class="Bold">increase</span><span class="Bold"></span><span class="Bold">suicidal</span><span class="Bold"></span><span class="Bold">thoughts</span><span class="Bold"></span><span class="Bold">or</span><span class="Bold"></span><span class="Bold">actions</span><span class="Bold"></span><span class="Bold">in</span><span class="Bold"></span><span class="Bold">some</span><span class="Bold"></span><span class="Bold">children,</span><span class="Bold"></span><span class="Bold">teenagers,</span><span class="Bold"></span><span class="Bold">and</span><span class="Bold"></span><span class="Bold">young adults within the first few months of treatment.</span></span></li>
<li><span><span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></span><span class="Bold"></span><span class="Bold">and</span><span class="Bold"></span><span class="Bold">other</span><span class="Bold"></span><span class="Bold">serious</span><span class="Bold"></span><span class="Bold">mental</span><span class="Bold"></span><span class="Bold">illnesses</span><span class="Bold"></span><span class="Bold">are</span><span class="Bold"></span><span class="Bold">the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. </span>These include people who have (or have a family history of) bipolar illness (also called <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span>) or suicidal thoughts or actions.</span></li>
<li><span><span class="Bold">How</span><span class="Bold"></span><span class="Bold">can</span><span class="Bold"></span><span class="Bold">I watch for and try to prevent suicidal thoughts and actions in myself or a family member?</span></span></li>
</ol>
<ul>
<li><span>Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.</span></li>
<li>
<span>Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.</span><ul><li><span>Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.</span></li></ul>
</li>
</ul>
<p><span><span class="Bold">Call</span><span class="Bold"></span><span class="Bold">a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</span></span></p>
<ul>
<li><span>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</span></li>
<li><span>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></span></li>
<li><span>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></span></li>
<li><span>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></span></li>
<li><span>feeling very <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span></span></li>
<li><span><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></span></li>
<li>
<span>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>)</span><ul>
<li><span>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></span></li>
<li><span>acting aggressive, being angry, or violent</span></li>
<li><span>acting on dangerous impulses</span></li>
<li><span>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)</span></li>
<li><span>other unusual changes in behavior or mood</span></li>
</ul>
</li>
</ul>
<p><span><span class="Bold">What</span><span class="Bold"></span><span class="Bold">else</span><span class="Bold"></span><span class="Bold">do</span><span class="Bold"></span><span class="Bold">I need to know about antidepressant medicines?</span></span></p>
<ul>
<li><span><span class="Bold">Never</span><span class="Bold"></span><span class="Bold">stop an antidepressant medicine without first talking to a healthcare provider. </span>Stopping an antidepressant medicine suddenly can cause other symptoms.</span></li>
<li><span><span class="Bold">Antidepressants</span><span class="Bold"></span><span class="Bold">are</span><span class="Bold"></span><span class="Bold">medicines</span><span class="Bold"></span><span class="Bold">used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other illnesses. </span>It is important to discuss all the risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.</span></li>
<li><span><span class="Bold">Antidepressant</span><span class="Bold"></span><span class="Bold">medicines</span><span class="Bold"></span><span class="Bold">have</span><span class="Bold"></span><span class="Bold">other</span><span class="Bold"></span><span class="Bold">side</span><span class="Bold"></span><span class="Bold">effects.</span><span class="Bold"></span>Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.</span></li>
<li>
<span><span class="Bold">Antidepressant</span><span class="Bold"></span><span class="Bold">medicines</span><span class="Bold"></span><span class="Bold">can</span><span class="Bold"></span><span class="Bold">interact</span><span class="Bold"></span><span class="Bold">with</span><span class="Bold"></span><span class="Bold">other medicines. </span>Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.</span><ul><li><span><span class="Bold">Not</span><span class="Bold"></span><span class="Bold">all</span><span class="Bold"></span><span class="Bold">antidepressant</span><span class="Bold"></span><span class="Bold">medicines</span><span class="Bold"></span><span class="Bold">prescribed</span><span class="Bold"></span><span class="Bold">for</span><span class="Bold"></span><span class="Bold">children</span><span class="Bold"></span><span class="Bold">are</span><span class="Bold"></span><span class="Bold">FDA</span><span class="Bold"></span><span class="Bold">approved</span><span class="Bold"></span><span class="Bold">for</span><span class="Bold"></span><span class="Bold">use in children. </span>Talk to your child’s healthcare provider for more information.</span></li></ul>
</li>
</ul>
<p><span><span class="Bold">What</span><span class="Bold"></span><span class="Bold">is</span><span class="Bold"></span><span class="Bold">Aripiprazole?</span></span></p>
<ul><li>
<span><span class="Bold">Aripiprazole</span><span class="Bold"> Oral</span><span class="Bold"></span><span class="Bold">Solution</span><span class="Bold"></span>is prescription medicine used to treat:</span><ul>
<li><span><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></li>
<li><span><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes that happen with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span></span></li>
</ul>
</li></ul>
<p><span><span>It is not known if Aripiprazole is safe or effective in children: </span></span></p>
<ul>
<li><span><span>under 13 years of age with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> </span></span></li>
<li><span><span>under 10 years of age with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span><span class="Bold"></span></span></span></li>
</ul>
<p><span class="Bold"><span></span></span><span><span class="Bold">Who should not take Aripiprazole?</span></span></p>
<p> Do not take Aripiprazole if you are allergic to aripiprazole or any of the ingredients in Aripiprazole Oral Solution. See the end of this Medication Guide for a complete list of ingredients in Aripiprazole.</p>
<p> What should I tell my healthcare provider before taking Aripiprazole?</p>
<p></p>
<p>Before taking Aripiprazole, tell your healthcare provider if you have or had:</p>
<p></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or high blood sugar in you or your family; your healthcare provider should check your blood sugar before you start aripiprazole and also during therapy. </li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>). </li>
<li>low or high blood pressure. </li>
<li>heart problems or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. </li>
<li>pregnancy or plans to become pregnant. It is not known if aripiprazole will harm your unborn baby. </li>
<li>breast-feeding or plans to breast-feed. Aripiprazole can pass into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you receive Aripiprazole. </li>
<li>low white blood cell count. </li>
<li>any other medical conditions. </li>
</ul>
<p>Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. </p>
<p>Aripiprazole and other medicines may affect each other causing possible serious side effects. Aripiprazole may affect the way other medicines work, and other medicines may affect how Aripiprazole works. </p>
<p>Your healthcare provider can tell you if it is safe to take Aripiprazole with your other medicines. Do not start or stop any medicines while taking Aripiprazole without talking to your healthcare provider first. Know the medicines you take. Keep a list of your medicines to show your healthcare provider and pharmacist when you get a new medicine. </p>
<p>How should I take Aripiprazole?</p>
<p></p>
<ul>
<li>Take Aripiprazole exactly as your healthcare provider tells you to take it. Do not change the dose or stop taking Aripiprazole yourself. </li>
<li>Aripiprazole can be taken with or without food. </li>
<li>If you miss a dose of Aripiprazole, take the missed dose as soon as you remember. If it is almost time for the next dose, just skip the missed dose and take your next dose at the regular time. Do not take two doses of Aripiprazole at the same time. </li>
<li>If you take too much Aripiprazole, call your healthcare provider or poison control center at 1-800-222-1222 right away, or go to the nearest hospital emergency room. </li>
</ul>
<p>What should I avoid while taking Aripiprazole?</p>
<p></p>
<ul>
<li>Do not drive, operate heavy machinery, or do other dangerous activities until you know how Aripiprazole affects you. Aripiprazole may make you drowsy. </li>
<li>Avoid getting over-heated or dehydrated. </li>
<li>Do not over-exercise.</li>
<li>In hot weather, stay inside in a cool place if possible. </li>
<li>Stay out of the sun. Do not wear too much or heavy clothing. </li>
<li>Drink plenty of water.</li>
</ul>
<p> What are the possible side effects of Aripiprazole? </p>
<p>Aripiprazole may cause serious side effects, including:</p>
<p></p>
<ul>
<li>See “What is the most important information I should know about Aripiprazole?? </li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in elderly people (cerebrovascular problems) that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </li>
<li><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic malignant syndrome</span> (NMS). Tell your healthcare provider right away if you have some or all of the following symptoms: high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, stiff muscles, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, changes in pulse, heart rate, and blood pressure. These may be symptoms of a rare and serious condition that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Call your healthcare provider right away if you have any of these symptoms. </li>
<li>Uncontrolled body movements (<span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>). Aripiprazole may cause movements that you cannot control in your face, tongue, or other body parts. <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span> may not go away, even if you stop receiving Aripiprazole. <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span> may also start after you stop receiving Aripiprazole. </li>
<li>Problems with your metabolism such as: </li>
<li>high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>) and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Increases in blood sugar can happen in some people who take Aripiprazole. Extremely high blood sugar can lead to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (such as being overweight or a family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>), your healthcare provider should check your blood sugar before you start Aripiprazole and during your treatment.</li>
</ul>
<p></p>
<p>Call your healthcare provider if you have any of these symptoms of high blood sugar while receiving Aripiprazole:</p>
<p></p>
<ul>
<li>feel very thirsty </li>
<li>need to urinate more than usual </li>
<li>feel very hungry </li>
<li>feel weak or tired </li>
<li>feel sick to your stomach </li>
<li>feel <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span>, or your breath smells fruity </li>
<li>increased fat levels (<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides) in your blood. </li>
<li><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. You and your healthcare provider should check your weight regularly. </li>
<li><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> (decreased blood pressure). <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Lightheadedness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> may happen when rising too quickly from a sitting or lying position. </li>
<li>Low white blood cell count </li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>) </li>
<li>problems with control of your body temperature especially when you exercise a lot or are in an area that is very hot. It is important for you to drink water to avoid <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. See “What should I avoid while receiving Aripiprazole?? </li>
<li>difficulty swallowing that can cause food or liquid to get into your lungs. </li>
</ul>
<p>The most common side effects of Aripiprazole in adults include: </p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></span></p></td>
<td><span><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span><span class="Bold"></span></span></td>
</tr>
<tr>
<td><span><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><span class="Bold"></span></span></td>
<td><span><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span><span class="Bold"></span></span></td>
</tr>
<tr>
<td><span><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span><span class="Bold"></span></span></td>
<td><span><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span><span class="Bold"></span></span></td>
</tr>
<tr>
<td><span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span><span class="Bold"></span></span></td>
<td><span><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span><span class="Bold"></span></span></td>
</tr>
<tr>
<td><span><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span><span class="Bold"></span></span></td>
<td><span>inner sense of <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>/need to move(<span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>)<span class="Bold"></span></span></td>
</tr>
<tr class="Last">
<td><span>upper respiratory illness<span class="Bold"></span></span></td>
<td><p class="First"><span class="Bold"><span></span></span></p></td>
</tr>
</tbody></table>
<p> The most common side effects of Aripiprazole in children include:</p>
<table width="535px"><tbody class="Headless">
<tr class="First">
<td><p class="First"><span>feeling <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span></span></p></td>
<td><span><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span><span class="Bold"></span></span></td>
</tr>
<tr>
<td><span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span><span class="Bold"></span></span></td>
<td><span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span><span class="Bold"></span></span></td>
</tr>
<tr>
<td><span><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><span class="Bold"></span></span></td>
<td><span>stuffy nose<span class="Bold"></span></span></td>
</tr>
<tr>
<td><span><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span><span class="Bold"></span></span></td>
<td><span><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span><span class="Bold"></span></span></td>
</tr>
<tr>
<td><span>increased or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></span></td>
<td><span>uncontrolled movement such as <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle stiffness</span><span class="Bold"></span></span></td>
</tr>
<tr class="Last"><td><span>increased saliva or <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span><span class="Bold"></span></span></td></tr>
</tbody></table>
<p> These are not all the possible side effects of Aripiprazole. For more information, ask your healthcare provider or pharmacist.</p>
<p> Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p> How should I store Aripiprazole?<span></span></p>
<p></p>
<ul>
<li>Store A<span>ripiprazole</span> at room temperature, between 68°F to 77°F (20°C to 25°C). </li>
<li>Opened bottles of Aripiprazole Oral Solution can be used for up to 6 months after opening, but not beyond the expiration date on the bottle. </li>
</ul>
<p>Keep Aripiprazole and all medicines out of the reach of children. </p>
<p>General information about the safe and effective use of Aripiprazole. </p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Aripiprazole for a condition for which it was not prescribed. Do not give Aripiprazole to other people, even if they have the same symptoms you have. It may harm them.</p>
<p></p>
<p>This Medication Guide summarizes the most important information about Aripiprazole. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about Aripiprazole that was written for healthcare professionals. </p>
<p>What are the ingredients in Aripiprazole? Active ingredient: aripiprazole  </p>
<p></p>
<p>Inactive ingredients: <span>butylated hydroxyanisole, methylparaben, phosphoric acid, propylene glycol, propylparaben, sodium hydroxide, sucralose, and purified water. The oral solution is flavored with orange flavors.</span></p>
<p></p>
<p><span></span><span>Additional pediatric use information is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.</span><span></span></p>
<p></p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration. </p>
<p>
             All registered trademarks are the property of their respective owners.
            </p>
<p></p>
<p><span>Manufactured by:</span></p>
<p><span>Silarx Pharmaceuticals, Inc.</span></p>
<p><span>Carmel, NY 10512 USA</span><span></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<div class="Figure"><img alt="Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7292c4c-e332-4ed4-9086-f130d223b6ae&amp;name=carton.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ARIPIPRAZOLE ORAL SOLUTION 		
					</strong><br><span class="contentTableReg">aripiprazole solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54838-570</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ARIPIPRAZOLE</strong> (ARIPIPRAZOLE) </td>
<td class="formItem">ARIPIPRAZOLE</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYANISOLE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHOSPHORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCRALOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54838-570-59</td>
<td class="formItem">150 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54838-570-70</td>
<td class="formItem">237 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA204171</td>
<td class="formItem">08/17/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Silarx Pharmaceuticals, Inc
							(161630033)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Silarx Pharmaceuticals, Inc</td>
<td class="formItem"></td>
<td class="formItem">161630033</td>
<td class="formItem">ANALYSIS(54838-570), LABEL(54838-570), PACK(54838-570), MANUFACTURE(54838-570)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b6b80c91-c208-490f-840d-474259429bd5</div>
<div>Set id: e7292c4c-e332-4ed4-9086-f130d223b6ae</div>
<div>Version: 3</div>
<div>Effective Time: 20150818</div>
</div>
</div> <div class="DistributorName">Silarx Pharmaceuticals, Inc</div></p>
</body></html>
